Bis-(-)-nor-meptazinols as Novel Nanomolar Cholinesterase Inhibitors with High Inhibitory Potency on Amyloid-beta Aggregation

J.Med.Chem.2008,51,2027-2036 Bis-()-nor-meptazinols as Novel Nanomolar Cholinesterase Inhibitors with High Inhibitory Potency on Amyloid-B Aggregation Qiong Xie, "Hao Wang, t* Zheng Xia, Meiyan Lu, t Weiwei Zhang. Xinghai Wang, t Wei Fu, t Yun Tang, Wei Sheng, Wei Li, Wei Zhou, Xu Zhu, Zhuibai Qiu, *f and Hongzhuan Chen*+ Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 138 Yixueyuan Road, Shanghai 200032, P. R. China, Departmen of Pharmacology, Institute of Medical Sciences, Shanghai JiaoTong University School of Medicine, 280 South Chongqing Road, 30 Meilong Road, Shanghai 200237, P. R. China Received February 9. 2007 Bis-(-)-nor-meptazinols(bis-()-nor-MEPs)5 were designed and synthesized by connecting two MEP monomers with alkylene linkers of different lengths via the secondary amino groups acetylcholinesterase(AChE) inhibitory activities were more greatly influenced by the length of the Alkylene exhibited low-nanomolar ICso values for both ChEs, having a 10 000-fold and 1500-fold increase in inhibitic of AChE and BChE compared with(-)-MEP. Molecular docking elucidated that 5h simultaneously bound to the catalytic and peripheral sites in AChE via hydrophobic interactions with Trp86 and Trp286. In comparison, it folded in the large aliphatic cavity of BChE because of the absence of peripheral site and the enlargement of the active site. Furthermore, 5h and 5i markedly prevented the AChE-induced AB aggregation with ICso values of 16.6 and 5.8 uM, similar to that of propidium (IC50= 12. 8 uM), which suggests promising disease-modifying agents for the treatment of AD patients Introduction Alzheimer's disease(AD), which is characterized by progres- sive loss of memory and impairment in cognition, is becoming a serious threat to life expectancy for elderly people. The main pathological changes in the Ad brain are the abnormal formation Linked of extracellular senile plaques consisting of aggregated amyloid B-peptide(Ap)deposits and intracellular neurofibrillary tangles (NTFs) consisting of abnormally phosphorylated microtubule- associated protein T Current clinical therapy for Ad patients is mainly palliative = atalytic site treatment targeting acetylcholinesterase(AChE). On the basis of the cholinergic hypothesis, inhibition of AChE effectively ncreases the available acetylcholine(ACh) within cholinergic synapses, resulting in modest improvement in cognitive symp- Figure 1. Catalytic and peripheral sites of AChE active site gorge oms. Mounting evidence has indicated that AChE may be involved in several noncholinergic functions. AChE colocalizes cognitive deficit of AD patients by elevating ACh levels but with AB in senile plaques, promoting the assembly of AB into also act as disease-modifying agents delaying amyloid plaque fibrils'and accelerating AB peptide deposition. Structural formation. 9a, 13 models of the interaction between AChE and AB have recently Recently, bivalent ligand strategy has been utilized in the been explored. It has been speculated that AChE achieves design of dual binding site ache inhibitors 9-13 homobivalent aggregation-promoting action through direct binding with A or heterobivalent ligands are obtained by connecting two via the specific region of the enzyme that involves a peripheral identical or distinct moieties through a linker of suitable length binding site. Inhibition of the peripheral site might prevent A, to make contact with both the catalytic and peripheral sites. A peptide deposition induced by AChE. This enzyme has a narrow spatial 12 A distance was determined by X-ray crystal diffraction 20 A deep active site gorge, the bottom and opening regions of from Trp86(mammalian numbering), the catalytic anionic site which are known as catalytic and peripheral sites, respectively center, to Trp286(mammalian numbering), core of the periph (Figure 1). AChE inhibitors simultaneously blocking both the eral site(Figure 1). In many cases of homobivalent ligands catalytic and peripheral sites might not only alleviate the (bis-ligands ), AChE inhibitory potency and selectivity improved relative to the monomer and additional inhibition of ache- 21地0m1 hE inhibitor reported g aoli@shamu.edu.cn strategy, presenting a more than 1000-fold increase in AChE Fudan inhibiting potency and a 10000-fold increase in AChE/butyryl These authors contributed equally to this work cholinesterase (BChE) selectivity compared with tacrine Shanghai Jiao Tong University. Bis-galanthamine 2(Figure 2, n=8), bis-5-amino-5,6,7, 8- East China University of Science and Technology 10 or 12) 10. 1021/jm070154q CCC: $.75 C 2008 American Chemical Society Published on web 03/12/2008

Bis-(-)-nor-meptazinols as Novel Nanomolar Cholinesterase Inhibitors with High Inhibitory Potency on Amyloid-
Aggregation Qiong Xie,†,# Hao Wang,‡,# Zheng Xia,‡ Meiyan Lu,† Weiwei Zhang,‡ Xinghai Wang,† Wei Fu,† Yun Tang,§ Wei Sheng,† Wei Li,† Wei Zhou,‡ Xu Zhu,‡ Zhuibai Qiu,*,† and Hongzhuan Chen*,‡ Department of Medicinal Chemistry, School of Pharmacy, Fudan UniVersity, 138 Yixueyuan Road, Shanghai 200032, P. R. China, Department of Pharmacology, Institute of Medical Sciences, Shanghai JiaoTong UniVersity School of Medicine, 280 South Chongqing Road, Shanghai 200025, P. R. China, and School of Pharmacy, East China UniVersity of Science and Technology, 130 Meilong Road, Shanghai 200237, P. R. China ReceiVed February 9, 2007 Bis-(-)-nor-meptazinols (bis-(-)-nor-MEPs) 5 were designed and synthesized by connecting two (-)-nor￾MEP monomers with alkylene linkers of different lengths via the secondary amino groups. Their acetylcholinesterase (AChE) inhibitory activities were more greatly influenced by the length of the alkylene chain than butyrylcholinesterase (BChE) inhibition. The most potent nonamethylene-tethered dimer 5h exhibited low-nanomolar IC50 values for both ChEs, having a 10 000-fold and 1500-fold increase in inhibition of AChE and BChE compared with (-)-MEP. Molecular docking elucidated that 5h simultaneously bound to the catalytic and peripheral sites in AChE via hydrophobic interactions with Trp86 and Trp286. In comparison, it folded in the large aliphatic cavity of BChE because of the absence of peripheral site and the enlargement of the active site. Furthermore, 5h and 5i markedly prevented the AChE-induced A
aggregation with IC50 values of 16.6 and 5.8 µM, similar to that of propidium (IC50 ) 12.8 µM), which suggests promising disease-modifying agents for the treatment of AD patients. Introduction Alzheimer’s disease (AD), which is characterized by progres￾sive loss of memory and impairment in cognition,1 is becoming a serious threat to life expectancy for elderly people. The main pathological changes in the AD brain are the abnormal formation of extracellular senile plaques consisting of aggregated amyloid-
-peptide (A
) deposits and intracellular neurofibrillary tangles (NTFs) consisting of abnormally phosphorylated microtubule￾associated protein τ. 2 Current clinical therapy for AD patients is mainly palliative treatment targeting acetylcholinesterase (AChE). On the basis of the cholinergic hypothesis,3 inhibition of AChE effectively increases the available acetylcholine (ACh) within cholinergic synapses, resulting in modest improvement in cognitive symp￾toms. Mounting evidence has indicated that AChE may be involved in several noncholinergic functions.4 AChE colocalizes with A
in senile plaques, promoting the assembly of A
into fibrils5 and accelerating A
peptide deposition.6 Structural models of the interaction between AChE and A
have recently been explored.7 It has been speculated that AChE achieves its aggregation-promoting action through direct binding with A
via the specific region of the enzyme that involves a peripheral binding site.8 Inhibition of the peripheral site might prevent A
peptide deposition induced by AChE. This enzyme has a narrow 20 Å deep active site gorge, the bottom and opening regions of which are known as catalytic and peripheral sites, respectively (Figure 1). AChE inhibitors simultaneously blocking both the catalytic and peripheral sites might not only alleviate the cognitive deficit of AD patients by elevating ACh levels but also act as disease-modifying agents delaying amyloid plaque formation.9a,13 Recently, bivalent ligand strategy has been utilized in the design of dual binding site AChE inhibitors.9–13 Homobivalent or heterobivalent ligands are obtained by connecting two identical or distinct moieties through a linker of suitable length to make contact with both the catalytic and peripheral sites. A spatial 12 Å distance was determined by X-ray crystal diffraction from Trp86 (mammalian numbering), the catalytic anionic site center, to Trp286 (mammalian numbering), core of the periph￾eral site (Figure 1).14 In many cases of homobivalent ligands (bis-ligands), AChE inhibitory potency and selectivity improved relative to the monomer and additional inhibition of AChE￾induced A
aggregation was observed. Bis-tacrine 1 (Figure 2, n ) 7)9 was the first bivalent AChE inhibitor reported on this strategy, presenting a more than 1000-fold increase in AChE inhibiting potency and a 10000-fold increase in AChE/butyryl￾cholinesterase (BChE) selectivity compared with tacrine. Bis-galanthamine 2 (Figure 2, n ) 8),10 bis-5-amino-5,6,7,8- tetrahydroquinolinone 3 (Figure 2, n ) 10 or 12),11 and bis- * To whom correspondence should be addressed. For Z.Q.: phone, 86- 21-54237595; fax, 86-21-54237264; e-mail, zbqiu@shmu.edu.cn. For H.C.: phone, 86-21-63846590, extension 776450; fax, 86-21-64674721; e-mail, yaoli@shsmu.edu.cn. † Fudan University. # These authors contributed equally to this work. ‡ Shanghai JiaoTong University. § East China University of Science and Technology. Figure 1. Catalytic and peripheral sites of AChE active site gorge. J. Med. Chem. 2008, 51, 2027–2036 2027 10.1021/jm070154q CCC: $40.75  2008 American Chemical Society Published on Web 03/12/2008

2028 Journal of Medicinal Chemistry, 2008, VoL. 51, No. 7 Xie et al Me○ CH2) OMe 1 bis-tacrine 2 bis-galanthamine 3bs5-amin56,7,8 (CH2im N(CH2)N(CH2)m) M Figure 2. Structures of reported homobivalent AChE inhibitors and title compounds 5 Scheme 1. Synthesis of (-)-nor-MEP 8 7 8 huperzine B 4(Figure 2, m=2, n=10)(Figure 2)have also Scheme 2. Synthesis of 5a, b,e-k been reported. Our group has been interested in the study of meptazinol (MEP),a racemic marketed opioid analgesic with low addic tion liability, and its()-enantiomer, which has demonstrated moderate inhibition of AChE. We established an approach to the resolution of MEP in acceptable yields and determined the absolute configurations of(-)-MEP and(+)-MEP as S and R, respectively, by X-ray crystal structures. 17 Continuing with our 5(a-b, e- previous research to find new AChE inhibitors through the Reagents and conditions: (i)a, a-dihaloalkane(0.5 equiv), triethylamine molecular modeling of(-)-MEP derivatives, we describe here (2 equiv), acetonitrile, reflux, 2-5h, 35-83% the design, synthesis, pharmacological evaluation, and molecular docking of a series of homobivalent(-)-N-demethylmeptazinols (bis-(-)-nor-MEPs)5. Two identical (-)-nor-MEP units are Newly synthesized compounds were tested in vitro for AChE ind BChE inhibitory potency, and their selectivity for AChE connected by alkylene linkers of different lengths via the was calculated. A molecular docking study was performed on ondary amino groups in compound 5(Figure 2) A suitable length of the alkylene linker, together with ar mouse AChE (mAChE) and human bChe (hBChE) to il luminate the binding modes of the most potent compound 5h appropriate point of the coupling position, guarantees that bis- with both enzymes. Because of the unavailability of crystal ligand will simultaneously bind to the catalytic and peripheral lographic data of mouse BChE, hBChE was used instead sites of the enzyme. According to our predicted binding mode because of a high sequence identity. The ability of compounds of(-)-MEP in AChE active site, the azepane ring is locate 5g, 5h, and 5i to inhibit the AChE-induced AB aggregation in the middle of the gorge whereas the phenolic group is oriented compared with propidium iodine and the reference compound ()-MEP derivatives were designed as bis-(-)-nor-MEPs ()-MEP, was assessed by means of a thioflavin T-based linking, via a point in the azepane ring instead of the phenolic fluorometric assay. Cell viability was tested by MTT assay group(Figure 1). As to the chain length(number of methylene nun er in the case of tacrine- based bivalent ligands was 7.However, that might not be the case in our Results and Discussion study. To find the most potent compound in our series and Chemistry. The synthetic methodology employed for the discuss the effect of linker length on inhibitory potency, preparation of bis-(--nor-MEP derivatives 5 is illustrated in compounds possessing methylene spacers varying from 2 to 12 Schemes 1-3. Key step in this route is the N-demethylation of were synthesized (-)-MEP 6 producing(-)-nor-MEP 8. A few methods have

huperzine B 4 (Figure 2, m ) 2, n ) 10)12 (Figure 2) have also been reported. Our group has been interested in the study of meptazinol (MEP),15 a racemic marketed opioid analgesic with low addic￾tion liability, and its (-)-enantiomer, which has demonstrated moderate inhibition of AChE.16 We established an approach to the resolution of MEP in acceptable yields and determined the absolute configurations of (-)-MEP and (+)-MEP as S and R, respectively, by X-ray crystal structures.17 Continuing with our previous research to find new AChE inhibitors through the molecular modeling of (-)-MEP derivatives,18 we describe here the design, synthesis, pharmacological evaluation, and molecular docking of a series of homobivalent (-)-N-demethylmeptazinols (bis-(-)-nor-MEPs) 5. Two identical (-)-nor-MEP units are connected by alkylene linkers of different lengths via the secondary amino groups in compound 5 (Figure 2). A suitable length of the alkylene linker, together with an appropriate point of the coupling position, guarantees that bis￾ligand will simultaneously bind to the catalytic and peripheral sites of the enzyme. According to our predicted binding mode of (-)-MEP in AChE active site,18 the azepane ring is located in the middle of the gorge whereas the phenolic group is oriented down into the catalytic site at the bottom. Therefore, bivalent (-)-MEP derivatives were designed as bis-(-)-nor-MEPs linking, via a point in the azepane ring instead of the phenolic group (Figure 1). As to the chain length (number of methylene units), the optimal number in the case of tacrine-based bivalent ligands was 7.9,19 However, that might not be the case in our study. To find the most potent compound in our series and discuss the effect of linker length on inhibitory potency, compounds possessing methylene spacers varying from 2 to 12 were synthesized. Newly synthesized compounds were tested in vitro for AChE and BChE inhibitory potency, and their selectivity for AChE was calculated. A molecular docking study was performed on mouse AChE (mAChE) and human BChE (hBChE) to il￾luminate the binding modes of the most potent compound 5h with both enzymes. Because of the unavailability of crystal￾lographic data of mouse BChE, hBChE was used instead because of a high sequence identity. The ability of compounds 5g, 5h, and 5i to inhibit the AChE-induced A
aggregation, compared with propidium iodine and the reference compound (-)-MEP, was assessed by means of a thioflavin T-based fluorometric assay.20 Cell viability was tested by MTT assay for 5h and 5i. Results and Discussion Chemistry. The synthetic methodology employed for the preparation of bis-(-)-nor-MEP derivatives 5 is illustrated in Schemes 1-3. Key step in this route is the N-demethylation of (-)-MEP 6 producing (-)-nor-MEP 8. A few methods have Figure 2. Structures of reported homobivalent AChE inhibitors and title compounds 5. Scheme 1. Synthesis of (-)-nor-MEP 8a a Reagents and conditions: (i) (a) ClCOOEt, KHCO3, CHCl3, reflux, 1 h; (b) K2CO3 (aq), MeOH, N2, room temp, 1 h, 95%; (ii) 50% H2SO4, N2, reflux, 4 h, 54%. Scheme 2. Synthesis of 5a,b,e-ka a Reagents and conditions: (i) R,ω-dihaloalkane (0.5 equiv), triethylamine (2 equiv), acetonitrile, reflux, 2-5 h, 35-83%. 2028 Journal of Medicinal Chemistry, 2008, Vol. 51, No. 7 Xie et al

Journal of Medicinal Chemistry, 2008, Vol. 51, No. 7 2029 Scheme 3. Synthesis of 5c, d CH2)n-2 9(,d) been reported for the demethylation of tertiary amines, such as Table 1. Inhibition of AChE and BChE by Bis-(-)-nor-MEPs 5a-k ()MEP, and Rivastigmine employment of azodicarboxylic acid esters, cyanogen bro- ICso(nM) as the reagent, taking both the availability and reaction simplicity ice brain Mice serum selectivity for to account. treating MEP 6 with ethyl chloroformate in BChE the presence of KHCO3 in boiling CHCl3, followed by dealing 5a 43000±20000125±9 the resulting residue with a mild base, afforded a nonbasic 342000±14000132±510.0 carbamate intermediate, (-)-N-carboethoxy nor-MEP 7How 421400±7600104±290.0049 4000±1000192±41 0.048 ever, troubles were encountered in the hydrolysis and decar- se 1220±20 0.098 xylation of the resulting carbamate intermediate 7. Al 5f 7 270±70 102±19 reactions failed under the reported alkaline condition in KOH24 ±19 63±8 nd acidic conditions in hydrobromic acid or 25% sulfuric acid 3.9±1.3 10士3 Finally this transformation was accomplished in 50% sulfuric .5±4.5 74±11 acid under nitrogen for 4 h, and (-)-nor-MEP 8 was obtained 42±20 in a 54% yield(Scheme 1) rivastigmine 5500±15001600±300.29 Alkylation of (-)-nor-MEP 8 with a, o-dihaloalkanes(0.5 (一)MEP 41000±1400015000±40000.37 equiv) in the presence of triethylamine, followed by chromato- graphic purification, easily produced the bis-(-)-nor-MEP of AChE. Mice serum was the source of BChE. AChE was assayed compounds 5a, b e-k in 35-83% yield(Scheme 2). However. spectrophotometrically with acetylthiocholine as substrate in the presence Ikylation with 1, 4-dichlorobutane or 1, 5-dichloropentane failed with butyrylthiocholine as substrate and 1025 M BW284C51 as AChE to furnish the bivalent compounds 5c, d, since the N-4-chlo- inhibitor ICso values were computed by a nonlinear least squares regression robutyl (or 5-chloropentyl)-(-)-nor-MEP intermediate was prone program that also provided an estimate of statistical precision(standard to forming stable intramolecular five-membered or six error of the mean). Selectivity for AChE: ICso for BChE divided by ICso membered ring structures, resulting in failure to link another for AChE. )-nor-MEP unit and leading to the generation of spiro ■AChE◆BChE quaternary ammoniums Structures of two quaternary ammo- niums derived from the R enantiomer were confirmed by X-ray crystallographic diffraction. Eventually, the synthesis of the bis-ligands 5c, d was accomplished by acylation with a,a- Ikanediacyl dihalide(0.5 equiv) to form bis-amides intermedi- ates 9c, d followed by reduction using lithium aluminum hydride (LAH) in tetrahydrofuran(THF)(Scheme 3) The chemical structures of all target compounds or their ynthesized hydrochloride salts were characterized by specific rotation [a]D, IR, H NMR, and HR-ESI, as reported in the 5269只 Experimental Section. The complicated property of NMR data from bis-(-)-nor-MEP hydrochloride salts in DMSO-d6 re- sembled the case of (+)-MEP hydrochloride. It was reasonably explained by conformational switch of the azepane ring and onfigurational inversion of nitrogen AChE Inhibitory Potency and AChE/BChE Selectivity Newly synthesized compounds were tested in vitro for potency 即mh时nr and selectivity as cholinesterase( ChE)inhibitors. Extracts from mice brain and mice serum were used as sources of AChE and the length of the alkylene chain. The optimal chain length BChE, respectively. The results showed that both(-)-MEP and determined experimentally was achieved in compound 5h, with its bis-ligand analogues possessed ChE inhibitory activity. The nine methylene groups between two (-)-nor-MEP units 50 value of(-)-MEP was 41 uM, about 10 times higher than Compared with(-)-MEP (ICso=41 uM)and rivastigmine(ICso that obtained with AChE from bovine erythrocytes, and the=5.5 uM), 5h(ICs0=3.9 nM) showed a 10000-fold and 1400 testing data of the reference drug rivastigmine conformed to fold increase, respectively, in the inhibition of mice brain AChE the previous report 27 The AChE inhibitory potency within the (Table 1). Further decrease or increase of the chain length series of bis-(-)-nor-MEP derivatives was closely related to weakened the AChE inhibition(Figure 3). For instan

been reported for the demethylation of tertiary amines, such as employment of azodicarboxylic acid esters,21 cyanogen bro￾mide,22 or chloroformates.23,24 Ethyl chloroformate was chosen as the reagent, taking both the availability and reaction simplicity into account. Treating (-)-MEP 6 with ethyl chloroformate in the presence of KHCO3 in boiling CHC13, followed by dealing the resulting residue with a mild base, afforded a nonbasic carbamate intermediate, (-)-N-carboethoxy nor-MEP 7. How￾ever, troubles were encountered in the hydrolysis and decar￾boxylation of the resulting carbamate intermediate 7. All reactions failed under the reported alkaline condition in KOH24 and acidic conditions in hydrobromic acid or 25% sulfuric acid. Finally this transformation was accomplished in 50% sulfuric acid under nitrogen for 4 h, and (-)-nor-MEP 8 was obtained in a 54% yield (Scheme 1). Alkylation of (-)-nor-MEP 8 with R,ω-dihaloalkanes (0.5 equiv) in the presence of triethylamine, followed by chromato￾graphic purification, easily produced the bis-(-)-nor-MEP compounds 5a,b,e-k in 35-83% yield (Scheme 2). However, alkylation with 1,4-dichlorobutane or 1,5-dichloropentane failed to furnish the bivalent compounds 5c,d, since the N-4-chlo￾robutyl (or 5-chloropentyl)-(-)-nor-MEP intermediate was prone to forming stable intramolecular five-membered or six￾membered ring structures, resulting in failure to link another (-)-nor-MEP unit and leading to the generation of spiro quaternary ammoniums. Structures of two quaternary ammo￾niums derived from the R enantiomer were confirmed by X-ray crystallographic diffraction.25 Eventually, the synthesis of the bis-ligands 5c,d was accomplished by acylation with R,ω- alkanediacyl dihalide (0.5 equiv) to form bis-amides intermedi￾ates 9c,d followed by reduction using lithium aluminum hydride (LAH) in tetrahydrofuran (THF) (Scheme 3). The chemical structures of all target compounds or their synthesized hydrochloride salts were characterized by specific rotation [R]D, IR, 1 H NMR, and HR-ESI, as reported in the Experimental Section. The complicated property of NMR data from bis-(-)-nor-MEP hydrochloride salts in DMSO-d6 re￾sembled the case of (+)-MEP hydrochloride.26 It was reasonably explained by conformational switch of the azepane ring and configurational inversion of nitrogen. AChE Inhibitory Potency and AChE/BChE Selectivity. Newly synthesized compounds were tested in vitro for potency and selectivity as cholinesterase (ChE) inhibitors. Extracts from mice brain and mice serum were used as sources of AChE and BChE, respectively. The results showed that both (-)-MEP and its bis-ligand analogues possessed ChE inhibitory activity. The IC50 value of (-)-MEP was 41 µM, about 10 times higher than that obtained with AChE from bovine erythrocytes,16 and the testing data of the reference drug rivastigmine conformed to the previous report.27 The AChE inhibitory potency within the series of bis-(-)-nor-MEP derivatives was closely related to the length of the alkylene chain. The optimal chain length determined experimentally was achieved in compound 5h, with nine methylene groups between two (-)-nor-MEP units. Compared with (-)-MEP (IC50 ) 41 µM) and rivastigmine (IC50 ) 5.5 µM), 5h (IC50 ) 3.9 nM) showed a 10000-fold and 1400- fold increase, respectively, in the inhibition of mice brain AChE (Table 1). Further decrease or increase of the chain length weakened the AChE inhibition (Figure 3). For instance, the Scheme 3. Synthesis of 5c,da a Reagents and conditions: (i) R,ω-alkanediacyl dihalide (0.5 equiv), triethylamine (2 equiv), dry CH2Cl2, 0 °C, 15 min, 38-41%; (ii) lithium aluminum hydride (LAH), dry THF, reflux, 1 h, 31-36%. Table 1. Inhibition of AChE and BChE by Bis-(-)-nor-MEPs 5a-k, (-)-MEP, and Rivastigminea IC50 (nM) compd chain length (n) mice brain AChE Mice serum BChE selectivity for AChEb 5a 2 43000 ( 20000 125 ( 9 0.0029 5b 3 42000 ( 14000 132 ( 51 0.0031 5c 4 21400 ( 7600 104 ( 29 0.0049 5d 5 4000 ( 1000 192 ( 41 0.048 5e 6 1220 ( 20 119 ( 20 0.098 5f 7 270 ( 70 102 ( 19 0.38 5g 8 79 ( 19 63 ( 8 0.80 5 h 9 3.9 ( 1.3 10 ( 3 2.6 5i 10 9.5 ( 4.5 17 ( 6 1.8 5j 11 24 ( 8 74 ( 11 3.1 5k 12 42 ( 20 100 ( 55 2.4 rivastigmine 5500 ( 1500 1600 ( 30 0.29 (-)-MEP 41000 ( 14000 15000 ( 4000 0.37 a Mice brain homogenate prepared in normal saline was used as a source of AChE. Mice serum was the source of BChE. AChE was assayed spectrophotometrically with acetylthiocholine as substrate in the presence of 1024 M ethopropazine as BChE inhibitor. BChE was assayed similarly with butyrylthiocholine as substrate and 1025 M BW284C51 as AChE inhibitor. IC50 values were computed by a nonlinear least squares regression program that also provided an estimate of statistical precision (standard error of the mean). b Selectivity for AChE: IC50 for BChE divided by IC50 for AChE. Figure 3. Correlation between ChE inhibitory potency (-log(IC50)) and the alkylene chain length (n) in compounds 5. Bis-(-)-nor-meptazinols as Inhibitors Journal of Medicinal Chemistry, 2008, Vol. 51, No. 7 2029

2030 Journal of Medicinal Chemistry, 2008, VoL. 51, No. 7 Xie et al inhibitory activities of 5a and 5b(43 and 42 uM, respectively) buried within the core of the enzyme binds with the catalytic are similar to that of(-)-MEP. Therefore, the effective alkylene site via face-to-face T-stacking interaction with Trp86(distance bridged bis-(-)-nor-MEP analogues required chains of suitable between the two centroids: 4.27 A). The other nor-MEP moiety length, which was 9 for the best, to bind at both the catalytic reaches the peripheral site on the surface of the enzyme by site and the peripheral site of the AChE binding pocket(gorge). cation-T and hydrophobic interactions between the seven- Compared with the AChE activity, the BChE inhibitory membered azepane ring and Trp286(distance between the two potency was less impacted by chain length(Figure 3). The centroids: 4.09 A). The spatial distance between the centroids ajority of bis-(-)-MEP analogues showed inhibition on BChE of the centric phenyl group and the peripheral azepane ring is of about 100 nM, although the highest potency (Cso=10 nM) 13.5 A, consistent with the reported distance between two was achieved in 5h. This isomer was 1500 times and 150 times tryptophane. 45h forms two hydrogen bonds, both in the more potent than(-)-MEP (ICso= 15 uM)and rivastigmine catalytic active site. The hydroxyl is hydrogen-bonded to the (Cso= 1.6 uM), respectively, but only 10 times lower than main-chain carbonyl oxygen of His447(O-O distance: 2.87 that of the majority compounds (Table 1). The reason that the A). Meanwhile, the protonated azepane amino group is hydrogen AChE inhibition seems to be the enzymic conformational A). In addition, other aliphatic and aromatic residues are difference. There is lack of a functional peripheral site involved in hydrophobic interactions BChE,2.29 and the BChE active site is wider throughout In the binding mode of 5h with the active sit Therefore, there is no restriction of linker length for bivalent of hBChE is shown in Figure 4c, d. 5h is folded in the large BChE inhibitors cavity along the aliphatic residue-dominated wall, and the Most bis-ligand analogues showed greater selectivity for separation of two terminal(-)-nor-MEP units is relatively short. BChE because of their low affinity for AChE. Only four Three hydrogen bonds are found: (i)between the phenolic compounds, 5h, 51, 5j, and 5k, demonstrated slightly more hydroxyl within the core of the enzyme and the carboxylic acid selectivity for AChE. Recent evidence suggests that both AChE xygen of Asp70(O-O distance, 2.49 A);(ii) between the R四hh图 nd progression of Carboxylic acid ox gen of GI.a21 the activity of AChE decreases progressively in certain regions and (ii) between the oxygen on the phenolic hydroxyl at the to reach 10-15% of normal values, whereas the activity of BChE entrance and the side chain amide nh of Ginl19(O.N stays unchanged or is even increased by 20%.30 Thus, it may distance,3.22 A). Ala 277 and Ala328 are not so importantly not be an advantage for a ChE inhibitor to be considerably more involved in the hydrophobic interactions with 5h, unlike the elective for AChE; on the contrary, a good balance between way their counterparts Try286 and Tyr337 in the mAChE AChE and BChE may result in higher efficacy. As a dual catalytic site behave. On the contrary, some residues unique to inhibitor of both AChE and BChE, rivastigmine appears to be hBChE, such as GInI 19, Leu286, and Val288, form hydrophobic beneficial for people with mild to moderate AD, and BChE contacts with 5h. nhibition correlates significantly with cognitive improvement The difference in the binding mode as well as in pharmace in these patients. In our study, although 5h is slightly more logical activities between 5h with AChE and BChE is funda selective for AChE than BChE (2.6), it had the greatest mentally caused by conformational differences between the two inhibition at a nanomolar lever on both enzymes. Therefore, it enzymes. One of the most important differences is the lack of as suggested that it was a promising drug candidate worthy peripheral site in BChE. Residues responsible for J-T or of further investigations. cation-T interactions at AChE peripheral site are replaced by Molecular Docking Studies. Molecular docking study was aliphatic residues in BChE. For example, Trp286, Tyr72, and performed to ascertain the possibility for the most potent Tyrl24 in mAChE are the counterparts of Ala277, Asn68, and ompound Sh to bind at both the catalytic and peripheral sites GInl1g in hBChE, respectively. In addition, some bulky of AChE and to explore the difference in the interactions of Sh aromatic residues in AChE active site have been replaced by with AChE and BChE. Mammalian enzymes were used in small aliphatic ones in BChE. As a result, the active site of docking, compatible with the pharmacological test. Because of BChE is wider and able to accommodate bis-ligands with linkers the unavailability of crystallographic data of mouse BChE. of wider-ranging lengths. These might be the main reasons that hBChE was used instead because there is a high sequence the bche inhibition is less sensitive to the linker length identity (82%)especially betwe ouse and human bche and Inhibition of A ChE-lnduced AB Aggregation. Three com- the residues in active sites are highly conservative. Here, we pounds, 5g, 5h, and 5i, were selected to assess their abilities to chose recently resolved X-ray crystal structures of the mAChE inhibit AB aggregation induced by AChE using a thioflavin complex with succinylcholine'with a high resolution of 2.05 T-based fluorometric assay, compared with the reference A and of native hBChE28 with a 2.0 A resolution. GOLD compound propidium iodine(Sigma-Aldrich), a known specific docking protocol was employed because it has been proved by peripheral site-binding inhibitor, and the monomer(-)-MEP our previous study to be accurate and reliable for reproducing (Table 2). Results showed that Sh and 5i markedly prevented the binding modes of seven AChE inhibitors in their X-ray the AChE-induced AB aggregation with ICso values of 16.6 and rystal structures of Torpedo californica AChE (TcAChE) 5.8 uM, similar to that of propidium(IC50= 12. 8 uM). With a complexes. An advanced consensus scoring technology was used small ICso value and a higher efficiency of inhibition, 5i and to guide the selection of the most reliable conformation from a 5h were the wonderful compounds that inhibited the aggregation set of candidate conformations that GOLD generated of AB induced by AChE. In contrast, (-)-MEP and 5g showed Our results show that Sh is able to simultaneously make fairly low inhibitory activity (Table 2), which indicated their ontact with both the catalytic and peripheral sites of mAChE, limited ability to interact with the peripheral site of the enzyme s illustrated in Figure 4a. The key interactions of these dimeric Different behaviors of these four compounds were attributed inhibitors with the catalytic and peripheral sites are T-stacking to different lengths of linker, demonstrating that a linker no and cation- interactions. The phenyl group of the nor-MEP horter than 9 was necessary to inhibit AChE-induced A

inhibitory activities of 5a and 5b (43 and 42 µM, respectively) are similar to that of (-)-MEP. Therefore, the effective alkylene￾bridged bis-(-)-nor-MEP analogues required chains of suitable length, which was 9 for the best, to bind at both the catalytic site and the peripheral site of the AChE binding pocket (gorge). Compared with the AChE activity, the BChE inhibitory potency was less impacted by chain length (Figure 3). The majority of bis-(-)-MEP analogues showed inhibition on BChE of about 100 nM, although the highest potency (IC50 ) 10 nM) was achieved in 5h. This isomer was 1500 times and 150 times more potent than (-)-MEP (IC50 ) 15 µM) and rivastigmine (IC50 ) 1.6 µM), respectively, but only 10 times lower than that of the majority compounds (Table 1). The reason that the BChE inhibition is less sensitive to the linker length than the AChE inhibition seems to be the enzymic conformational difference. There is lack of a functional peripheral site in BChE,28,29 and the BChE active site is wider throughout. Therefore, there is no restriction of linker length for bivalent BChE inhibitors. Most bis-ligand analogues showed greater selectivity for BChE because of their low affinity for AChE. Only four compounds, 5h, 5i, 5j, and 5k, demonstrated slightly more selectivity for AChE. Recent evidence suggests that both AChE and BChE may play roles in the etiology and progression of AD beyond regulation of synaptic ACh levels. In the AD brain, the activity of AChE decreases progressively in certain regions to reach 10–15% of normal values, whereas the activity of BChE stays unchanged or is even increased by 20%.30 Thus, it may not be an advantage for a ChE inhibitor to be considerably more selective for AChE; on the contrary, a good balance between AChE and BChE may result in higher efficacy. As a dual inhibitor of both AChE and BChE, rivastigmine appears to be beneficial for people with mild to moderate AD, and BChE inhibition correlates significantly with cognitive improvement in these patients.31 In our study, although 5h is slightly more selective for AChE than BChE (2.6), it had the greatest inhibition at a nanomolar lever on both enzymes. Therefore, it was suggested that it was a promising drug candidate worthy of further investigations. Molecular Docking Studies. Molecular docking study was performed to ascertain the possibility for the most potent compound 5h to bind at both the catalytic and peripheral sites of AChE and to explore the difference in the interactions of 5h with AChE and BChE. Mammalian enzymes were used in docking, compatible with the pharmacological test. Because of the unavailability of crystallographic data of mouse BChE, hBChE was used instead because there is a high sequence identity (82%) especially between mouse and human BChE and the residues in active sites are highly conservative. Here, we chose recently resolved X-ray crystal structures of the mAChE complex with succinylcholine32 with a high resolution of 2.05 Å and of native hBChE28 with a 2.0 Å resolution. GOLD33 docking protocol was employed because it has been proved by our previous study18 to be accurate and reliable for reproducing the binding modes of seven AChE inhibitors in their X-ray crystal structures of Torpedo californica AChE (TcAChE) complexes. An advanced consensus scoring technology was used to guide the selection of the most reliable conformation from a set of candidate conformations that GOLD generated. Our results show that 5h is able to simultaneously make contact with both the catalytic and peripheral sites of mAChE, as illustrated in Figure 4a. The key interactions of these dimeric inhibitors with the catalytic and peripheral sites are π-stacking and cation-π interactions. The phenyl group of the nor-MEP buried within the core of the enzyme binds with the catalytic site via face-to-face π-stacking interaction with Trp86 (distance between the two centroids: 4.27 Å). The other nor-MEP moiety reaches the peripheral site on the surface of the enzyme by cation-π and hydrophobic interactions between the seven￾membered azepane ring and Trp286 (distance between the two centroids: 4.09 Å). The spatial distance between the centroids of the centric phenyl group and the peripheral azepane ring is 13.5 Å, consistent with the reported distance between two tryptophanes.14 5h forms two hydrogen bonds, both in the catalytic active site. The hydroxyl is hydrogen-bonded to the main-chain carbonyl oxygen of His447 (O ··· O distance: 2.87 Å). Meanwhile, the protonated azepane amino group is hydrogen￾bonded to the hydroxyl oxygen of Tyr124 (N···O distance: 3.22 Å). In addition, other aliphatic and aromatic residues are involved in hydrophobic interactions, as shown in Figure 4b. In comparison, the binding mode of 5h with the active site of hBChE is shown in Figure 4c,d. 5h is folded in the large cavity along the aliphatic residue-dominated wall, and the separation of two terminal (-)-nor-MEP units is relatively short. Three hydrogen bonds are found: (i) between the phenolic hydroxyl within the core of the enzyme and the carboxylic acid oxygen of Asp70 (O ··· O distance, 2.49 Å); (ii) between the phenolic hydroxyl at the entrance of the enzyme and the carboxylic acid oxygen of Glu276 (O ··· O distance, 2.61 Å); and (iii) between the oxygen on the phenolic hydroxyl at the entrance and the side chain amide NH of Gln119 (O ··· N distance, 3.22 Å). Ala 277 and Ala328 are not so importantly involved in the hydrophobic interactions with 5h, unlike the way their counterparts Try286 and Tyr337 in the mAChE catalytic site behave. On the contrary, some residues unique to hBChE, such as Gln119, Leu286, and Val288, form hydrophobic contacts with 5h. The difference in the binding mode as well as in pharmaco￾logical activities between 5h with AChE and BChE is funda￾mentally caused by conformational differences between the two enzymes. One of the most important differences is the lack of peripheral site in BChE. Residues responsible for π-π or cation-π interactions at AChE peripheral site are replaced by aliphatic residues in BChE. For example, Trp286, Tyr72, and Tyr124 in mAChE are the counterparts of Ala277, Asn68, and Gln119 in hBChE, respectively. In addition, some bulky aromatic residues in AChE active site have been replaced by small aliphatic ones in BChE. As a result, the active site of BChE is wider and able to accommodate bis-ligands with linkers of wider-ranging lengths. These might be the main reasons that the BChE inhibition is less sensitive to the linker length. Inhibition of AChE-Induced A
Aggregation. Three com￾pounds, 5g, 5h, and 5i, were selected to assess their abilities to inhibit A
aggregation induced by AChE using a thioflavin T-based fluorometric assay,20 compared with the reference compound propidium iodine (Sigma-Aldrich), a known specific peripheral site-binding inhibitor, and the monomer (-)-MEP (Table 2). Results showed that 5h and 5i markedly prevented the AChE-induced A
aggregation with IC50 values of 16.6 and 5.8 µM, similar to that of propidium (IC50 ) 12.8 µM). With a small IC50 value and a higher efficiency of inhibition, 5i and 5h were the wonderful compounds that inhibited the aggregation of A
induced by AChE. In contrast, (-)-MEP and 5g showed fairly low inhibitory activity (Table 2), which indicated their limited ability to interact with the peripheral site of the enzyme. Different behaviors of these four compounds were attributed to different lengths of linker, demonstrating that a linker no shorter than 9 was necessary to inhibit AChE-induced A
2030 Journal of Medicinal Chemistry, 2008, Vol. 51, No. 7 Xie et al

Journal of Medicinal Chemistry, 2008, Vol. 51, No. 7 2031 Gly 1a277 TYr 33 His 4 -Asp 74 33l288 115 如 48 b d Ligand bond His 53 Non-hgand residues involved in hydrophobic Non-lisand bond Om contact(s) ●-● Hvdrogen bond and its length Figure 4. Representation of 5h colored green) docked into the binding sites of mAChe (a) and hbChe (c). The binding site surfaces are colored according to the vacuum statics protein contact potential, calculated by PyMoL 0.99rc2(DeLano Scientific LLC, San Carlos, CA) Crucial catalytic and peripheral he counterpart)residues are colored yellow. Hydrogen bonds and hydrophobic contacts between 5h and the rotein residues of mAChE (b) I site (or the ChE(d)are shown by Lig Plot 4.4.2. 41 aggregation. These findings agree with the results from enzy-(--)-nor-MEPs 5. Their AChE inhibitory activities were closely natic test and molecular docking, which indicated that a linker related to the length of the alkylene chain, whereas BChE of 9 or 10 methylenes would help to reach the peripheral site inhibition was less influenced. The optimal chain length for of achE AChE and BChE inhibition was achieved with 9 in 5h. which Cell Viability. The toxicity of the most po ent two bis 9(-) showed a 10000-fold and 1500-fold increase in the inhibition nor an neuroblastoma cell line of mice brain AChE and mice serum BChE, respectively SH-SY5Y. Cell viability was not affected for 5h and 5i at compared with(-)-MEP. Molecular docking elucidated that Sh concentrations of 1-100 uM(higher than the ICso values of 5h simultaneously bound to the catalytic and peripheral sites via and 5i against B-amyloid aggregation inhibition(around 80 uM) hydrophobic interactions with Trp86 and Trp286 in mAChE. and 10000 times higher than their AChE inhibiting ICso values) In comparison, it folded in the large aliphatic cavity of hBChE Conclusion The differences were explained by the absence of peripheral We have discovered novel nanomolar ChE inhibitors with site and the enlargement of the active site gorge in BChE h inhibitory potency on AB aggregation, i.e., a series of bis- Furthermore, 5h and 5i markedly prevented the AChE-induced

aggregation. These findings agree with the results from enzy￾matic test and molecular docking, which indicated that a linker of 9 or 10 methylenes would help to reach the peripheral site of AChE. Cell Viability. The toxicity of the most potent two bis-(-)- nor-MEPs was determined in human neuroblastoma cell line SH-SY5Y. Cell viability was not affected for 5h and 5i at concentrations of 1–100 µM (higher than the IC50 values of 5h and 5i against
-amyloid aggregation inhibition (around 80 µM) and 10000 times higher than their AChE inhibiting IC50 values). Conclusion We have discovered novel nanomolar ChE inhibitors with high inhibitory potency on A
aggregation, i.e., a series of bis- (-)-nor-MEPs 5. Their AChE inhibitory activities were closely related to the length of the alkylene chain, whereas BChE inhibition was less influenced. The optimal chain length for AChE and BChE inhibition was achieved with 9 in 5h, which showed a 10000-fold and 1500-fold increase in the inhibition of mice brain AChE and mice serum BChE, respectively, compared with (-)-MEP. Molecular docking elucidated that 5h simultaneously bound to the catalytic and peripheral sites via hydrophobic interactions with Trp86 and Trp286 in mAChE. In comparison, it folded in the large aliphatic cavity of hBChE. The differences were explained by the absence of peripheral site and the enlargement of the active site gorge in BChE. Furthermore, 5h and 5i markedly prevented the AChE-induced Figure 4. Representation of 5h (C atoms colored green) docked into the binding sites of mAChE (a) and hBChE (c). The binding site surfaces are colored according to the vacuum electrostatics protein contact potential, calculated by PyMOL 0.99rc2 (DeLano Scientific LLC, San Carlos, CA). Crucial catalytic and peripheral site (or the counterpart) residues are colored yellow. Hydrogen bonds and hydrophobic contacts between 5h and the protein residues of mAChE (b) and hBChE (d) are shown by LigPlot 4.4.2.41 Bis-(-)-nor-meptazinols as Inhibitors Journal of Medicinal Chemistry, 2008, Vol. 51, No. 7 2031

032 Journal of Medicinal Chemistry, 2008, VoL. 51, No. 7 Xie et al Table 2. Inhibition of AChE-Induced AB Aggregation by elution with EtoH/CHCI3 (0.8: 9.2 to 3: 7). The eluent was concen- Bis-(-H-nor-MEPs 5g-i and Reference Compounds trated in vacuo to afford 8(4.58 g, 54%0) Salt forming reaction of chain inhibition (%)at inhibition(%)at 8(1.07 g)was carried out in dry ether by adding dry HCl-ether mpd length(n) 200M and adjusting the pH to 4, which afforded 8. HCl as a white powder 856±44986±59128+04(93NMR①DMO4)942(HAOH,821ors12 98g,79%):mp73-75℃C;[alb-7.10°(c0.286,MeOH;IR )-MEP 0 15.2±0.2nd 90.8±0.2 2±0.116.6±0.5 6.74-6.65(m,3H,ArH),3.49(d,H,J=14.1Hz,N-CH2),3.21 958±0.5 984±0.158±0.3 (d,H,J=14.5Hz,N-CH2),3.08-3.00(m,2H,N-CH2),2.14 4 nd: not determined (m,H,CH2),1.77-155(m,7H,CH2),0.49(t,3H,J= B): MS (ESD)[M +H+220. AB aggregation with ICso values of 16.6 and 5.8 uM, compatible General Procedure for the Synthesis of Bis-(-)-Nor-MEP with that of propidium(IC50=12. 8 uM), which pointed out a promising disease-modifying action. Further pharmacological Compounds 5a, b, e-k. Triethylamine(2 equiv) and a, @-dihaloal study is needed to evaluate their abilities to reverse memory kane(0.5 equiv) were added to a solution of (-)-nor-MEP 8 in impairment in animal models in order to select ideal candidates acetonitrile. The reaction mixture was refluxed for 2-5 h Evapora tion of the solvent gave a residue, which was diluted with saturated for the treatment of AD patients K CO3 solution and extracted with CHCl3. The combined CHCls Experimental Sect extracts were dried (anhydrous Na2SO4) and evaporated under Chemistry. Melting points were taken in glass silica gel Eluting with petroleum ether/EtOAc(1: 2)afforded the and were uncorrected. Specific rotation (alp)was corresponding bis-(-)-nor-MEP compounds 5 as a yellow oil a JASCOP-1020 rotatory apparatus. IR data were on an Addition of dry HCI-ether to a solution of 5 in dry ether and AVATAR 360 FT-IR spectrometer(KBr). NMR data were recorded adjusting the ph to 3-4 gave the final salt 5. 2HCI as powder with a Mercury Plus 400 instrument. Chemical shifts(o)are N N-(1, 2-Ethylene)-bis-(-)-nor-MEP Hydrochloride(5a expressed in parts per million(ppm) relative to tetramethylsilane 2HCD) (-)-nor-MEP 8(1.50 g, 6.85 mmol), acetonitrile(15 mL). triethylamine (1.9 mL, 13.7 mmol), and 1, 2-dibromoethane(0. 297 disappeared after D2O exchange. Mass spectra were measured on mL, 3.43 mmol) were used to produce 5a(0.80 g, 50%). Subsequent an Agilent 1100 series LC/MSD 1946D spectrometer. HRMs salt formation gave 5a.2HCI(0.80 g, 86%0): mp 142-145C; [aID petra were recorded with an lon Spec 4.7 T FTMS instrument. 1.96°(c0.204,MeOH;Rv3176,2935,1599,1447,1229cm he purity of all target compounds(95%) was verified via HPLC. H NMR(DMSO-d6)10.84(br s, 1/2 H, NH*),10.58(br The elution was methanol-0.05 mol/L ammonium acetate sol NH+),9.51,9.49,943,9.34(s,2H,Ar-OH,909brs,12H, djustment of pH to 7. 4 with aqueous ammonia)(70: 30 to NH+),7.22-7.08(m,2H,Ar-H,6.83-6.61(m,6H,Ar-H) The chromatographic condition was a flow rate of 1.0 mL/mi 3.79-3.71(m,H,N-CH2),3.47-3.42(m,H,N-CH2),3.14-3.10 UV detection at 225 nm on a VP-ODS C18(150 mm x 4.6 mm (m,2H,N-CH2),3.03-2.86(m,6H,N-CH2),2.71-269(m,2H, 5 um)column at a temperature of 50C. All reagents were of N-CH2), 2.14-2.08( m, 2H, CH2), 1.84-1 46(m, 14H, CH2), 0.47 commercial quality. Rivastigmine hydrochloride standard was (m, 6H, CH3); MS(ESD) [M+ H] 465.6 HRMS m/z calcd for available from Sunve(Shanghai) Pharmaceutical Co, Ltd C30HasN2O [ M H, 465.3476: found, 465 3463. HPLC: IR (-)-N-Carboethoxy-nor-MEP (7). A stirred suspension of(-)- 4.48 min, 98.2% purity MEP 6(9.83 g, 42.2 mmol) and KHCO3 (74 g, 740 mmol)in sOiling CHCl3(500 mL) was treated with ethyl chloroformate(30.5 2HCD).(-)-nor-MEP8(1.54 g, 7.03 mmol), acetonitrile(15 mL) and the CHCl phase was separated and concentrated in vacuo. The mL, 3. 52 mmol)were used to produce Sb(1.20g.no 3197(r sidue was dissolved in MeOH (400 mL), treated with an aqu salt formation of 5b(0.90 g) gave 5b. 2HCI solution(400 mL) containing 66g of K2CO3, and stirred under N2 165-168C; [a]D-48.38(c 0.228, MeOH); IR at room temperature for 1 h After the MeOh was removed, the 1599, 1447, 1229 cm ; H NMR (DMSO-d6)10. 18, sidue was neutralized with 6 M HCI(126 mL)and extracted with 6/5 H, NH*), 9.58, 9.52, 944, 9.42(, 2H, Ar-OH),8.68,8.59 Et,0(150 mL x 3). The combined Et,O extracts were washed (br s, 4/5 H, NH), 7.20-7.13(m, 2H, Ar-H), 6.90-6. 65(m, 6H with saturated NaCl solution(150 mL) and dried with anhydrous Ar-H),3.92(, 4/5 H,J=14.5 Hz, N-CH2), 3.56(m, 6/5 H, Na2SO4 Evaporation of the solvent under reduced pressure gave 7 N-CH2,3.44-3.21(m, 10H, N-CH2, 2.40(m, 2H, CH2). 11.17 g, 95%)as a yellowish oil Recrystallization of 7(1.2 g) 2.10-1.50(m, 16H, CH2), 0.50(m, 6H, CH3); MS(ESD)[M from ethyl acetate(2 mL) afforded 7 as off-white crystals(0.64g, HI. 4, [M+ 2H] 240.2. HRMS m/z calcd for C31H47N2O2 53%):mp79-81C;alo-61.35°(c0.11,MeOH;HNM M+H+,479.3632; found,479.3641.HPLC:tk=700min, (CDCl3)7.18(t,H,J=7.8Hz,ArH),687-681(m,2H,ArH 6.70(d,H,J=8.0Hz,ArH,6.00(brs,1/2H,Ar-OH,5.57(br N, N-(1, 6-Hexylene)-bis-(-)-nor-MEP Hydrochloride (5e S, 1/2 H, Ar-OH), 4. 17-4.03(m, 2H, -OCH2), 3.94(d, H, N-CH2, 2HCI).(-)-nor-MEP 8(1.96g, 8.95 mmol), acetonitrile(20 mL) J= 14.6 Hz), 3.90-3.85(, 1/2 H, N-CH2CH3), 3.79-3. 73(m, triethy lamine (2.5 mL, 18.0 mmol), and 1, 6-dibromohexane(0.702 1/2 H, N-CH2), 3.52(d, 1/2H, J=14.4 Hz, N-CH2), 3.34(d, mL, 4.48 mmol) were used to produce 5e(0.96g, 41%) Subsequent l/2H,J=14.9Hz,N-CH2),3.06-295(m,H,N 20-2.05 salt formation gave 5e 2HCI (1.06g, 97%0): mp 13 CH3),-478°(c0.175,MeOH);IRv3414,31 2876,2732,1600, 0.56(t,3H,J=7.3H2,CH3);Ms(ESD)[M+ -)-Nor-MEP Hydrochloride(8.HCD). A mixture of 7(11. 17 2H, Ar-OHD),8.43,8.33(br s, 3/4 H, NH+), 7. 22-7.13.g2 Na]+3142,[M+K+330.2 1/2H,NH),9.80(brs,3/4H,NH+,956,9.53,9 g, 38.38 mmol) in 50% H,SOA(120 mL) was refluxed under N2 Ar-H). 6.87-6.76(m, 4H, Ar-H). 6.71-6.66(m, 2H, Ar-H), 3.84 for 4 h. The solution was treated with aqueous ammonia(180 mL), (m, 3/4 H. N-CH2), 3.55(m, 5/4 H, N-CH2). 3.34-3.09(m, 10H, dj usted to pH 9, and extracted with CHCl3(200 mL x 3). The N-CH2, 2.38(m, H, CH2), 2. 12-1.73(m, 15H, CH2), 1.57-1.4 mbined CHCla extracts were washed with saturated NaCl solution(m, 4H, CH2). 1.35-1.25(m, 4H, CH, ), 0.50(t, 6H,J=7.4 Hz (200 mL) and dried with anhydrous Na2SO4. The solvent was CH3): MS(ESD)[M+ H 521.7, [M+ 2H]- 261.4 HRMS m/z removed in vacuo, and the oily residue underwent chromatography calcd for C34HS3N2O2 [M H, 521.4102: found, 521.4086 on a column of 170 g of silica gel (200-300 mesh) and gradient HPLC: IR =810 min, 97.6% purity

A
aggregation with IC50 values of 16.6 and 5.8 µM, compatible with that of propidium (IC50 ) 12.8 µM), which pointed out a promising disease-modifying action. Further pharmacological study is needed to evaluate their abilities to reverse memory impairment in animal models in order to select ideal candidates for the treatment of AD patients. Experimental Section Chemistry. Melting points were taken in glass capillary tubes and were uncorrected. Specific rotation ([R]D) was determined on a JASCOP-1020 rotatory apparatus. IR data were taken on an AVATAR 360 FT-IR spectrometer (KBr). NMR data were recorded with a Mercury Plus 400 instrument. Chemical shifts (δ) are expressed in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard. All signals of active hydrogen disappeared after D2O exchange. Mass spectra were measured on an Agilent 1100 series LC/MSD 1946D spectrometer. HRMS spectra were recorded with an IonSpec 4.7 T FTMS instrument. The purity of all target compounds (>95%) was verified via HPLC. The elution was methanol-0.05 mol/L ammonium acetate solution (adjustment of pH to 7.4 with aqueous ammonia) (70:30 to 80:20). The chromatographic condition was a flow rate of 1.0 mL/min with UV detection at 225 nm on a VP-ODS C18 (150 mm × 4.6 mm, 5 µm) column at a temperature of 50 °C. All reagents were of commercial quality. Rivastigmine hydrochloride standard was available from Sunve (Shanghai) Pharmaceutical Co., Ltd. (-)-N-Carboethoxy-nor-MEP (7). A stirred suspension of (-)- MEP 6 (9.83 g, 42.2 mmol) and KHCO3 (74 g, 740 mmol) in boiling CHCl3 (500 mL) was treated with ethyl chloroformate (30.5 mL, 320 mmol) and refluxed for 1 h. H2O (350 mL) was added, and the CHCl3 phase was separated and concentrated in vacuo. The residue was dissolved in MeOH (400 mL), treated with an aqueous solution (400 mL) containing 66 g of K2CO3, and stirred under N2 at room temperature for 1 h. After the MeOH was removed, the residue was neutralized with 6 M HCl (126 mL) and extracted with Et2O (150 mL × 3). The combined Et2O extracts were washed with saturated NaCl solution (150 mL) and dried with anhydrous Na2SO4. Evaporation of the solvent under reduced pressure gave 7 (11.17 g, 95%) as a yellowish oil. Recrystallization of 7 (1.2 g) from ethyl acetate (2 mL) afforded 7 as off-white crystals (0.64 g, 53%): mp 79-81 °C; [R]D -61.35° (c 0.11, MeOH); 1 H NMR (CDCl3) 7.18 (t, H, J ) 7.8 Hz, ArH), 6.87–6.81 (m, 2H, ArH), 6.70 (d, H, J ) 8.0 Hz, ArH), 6.00 (br s, 1/2 H, Ar-OH), 5.57 (br s, 1/2 H, Ar-OH), 4.17–4.03 (m, 2H, -OCH2), 3.94 (d, H, N-CH2, J ) 14.6 Hz), 3.90–3.85 (m, 1/2 H, N-CH2CH3), 3.79–3.73 (m, 1/2 H, N-CH2), 3.52 (d, 1/2H, J ) 14.4 Hz, N-CH2), 3.34 (d, 1/2 H, J ) 14.9 Hz, N-CH2), 3.06–2.95 (m, H, N-CH2), 2.20–2.05 (m, H, CH2), 1.77–1.58 (m, 7H, CH2), 1.24 (m, 3H, -OCH2CH3), 0.56 (t, 3H, J ) 7.3 Hz, CH3); MS (ESI) [M + H]+ 292.2, [M + Na]+ 314.2, [M + K]+ 330.2. (-)-Nor-MEP Hydrochloride (8 ·HCl). A mixture of 7 (11.17 g, 38.38 mmol) in 50% H2SO4 (120 mL) was refluxed under N2 for 4 h. The solution was treated with aqueous ammonia (180 mL), adjusted to pH 9, and extracted with CHCl3 (200 mL × 3). The combined CHCl3 extracts were washed with saturated NaCl solution (200 mL) and dried with anhydrous Na2SO4. The solvent was removed in vacuo, and the oily residue underwent chromatography on a column of 170 g of silica gel (200-300 mesh) and gradient elution with EtOH/CHCl3 (0.8:9.2 to 3:7). The eluent was concen￾trated in vacuo to afford 8 (4.58 g, 54%). Salt forming reaction of 8 (1.07 g) was carried out in dry ether by adding dry HCl-ether and adjusting the pH to 4, which afforded 8 ·HCl as a white powder (0.98 g, 79%): mp 73-75 °C; [R]D -7.10° (c 0.286, MeOH); IR ν 3257, 2932, 1614, 1588, 1481, 1432, 1321, 1276, 1237, 1211 cm-1 ; 1 H NMR (DMSO-d6) 9.42 (s, H, Ar-OH), 8.82 (br s, 1/2 H, NH+), 8.24 (br s, 1/2 H, NH+), 7.16 (t, H, J ) 7.8 Hz, ArH), 6.74–6.65 (m, 3H, ArH), 3.49 (d, H, J ) 14.1 Hz, N-CH2), 3.21 (d, H, J ) 14.5 Hz, N-CH2), 3.08–3.00 (m, 2H, N-CH2), 2.14 (m, H, CH2), 1.77–1.55 (m, 7H, CH2), 0.49 (t, 3H, J ) 7.4 Hz, CH3); MS (ESI) [M + H]+ 220.1. HPLC: tR ) 1.86 min, 98.5% purity. General Procedure for the Synthesis of Bis-(-)-Nor-MEP Compounds 5a,b,e-k. Triethylamine (2 equiv) and R,ω-dihaloal￾kane (0.5 equiv) were added to a solution of (-)-nor-MEP 8 in acetonitrile. The reaction mixture was refluxed for 2-5 h. Evapora￾tion of the solvent gave a residue, which was diluted with saturated K2CO3 solution and extracted with CHCl3. The combined CHCl3 extracts were dried (anhydrous Na2SO4) and evaporated under reduced pressure. The residue was purified by chromatography on silica gel. Eluting with petroleum ether/EtOAc (1:2) afforded the corresponding bis-(-)-nor-MEP compounds 5 as a yellow oil. Addition of dry HCl-ether to a solution of 5 in dry ether and adjusting the pH to 3-4 gave the final salt 5 · 2HCl as powder. N,N′-(1′,2′-Ethylene)-bis-(-)-nor-MEP Hydrochloride (5a · 2HCl). (-)-nor-MEP 8 (1.50 g, 6.85 mmol), acetonitrile (15 mL), triethylamine (1.9 mL, 13.7 mmol), and 1,2-dibromoethane (0.297 mL, 3.43 mmol) were used to produce 5a (0.80 g, 50%). Subsequent salt formation gave 5a · 2HCl (0.80 g, 86%): mp 142-145 °C; [R]D -1.96° (c 0.204, MeOH); IR ν 3176, 2935, 1599, 1447, 1229 cm-1 ; 1 H NMR (DMSO-d6) 10.84 (br s, 1/2 H, NH+), 10.58 (br s, H, NH+), 9.51, 9.49, 9.43, 9.34(s, 2H, Ar-OH), 9.09 (br s, 1/2 H, NH+), 7.22–7.08 (m, 2H, Ar-H), 6.83–6.61 (m, 6H, Ar-H), 3.79–3.71 (m, H, N-CH2), 3.47–3.42 (m, H, N-CH2), 3.14–3.10 (m, 2H, N-CH2), 3.03–2.86 (m, 6H, N-CH2), 2.71–2.69 (m, 2H, N-CH2), 2.14–2.08 (m, 2H, CH2), 1.84–1.46 (m, 14H, CH2), 0.47 (m, 6H, CH3); MS (ESI) [M + H]+ 465.6. HRMS m/z calcd for C30H45N2O2 [M + H]+, 465.3476; found, 465.3463. HPLC: tR ) 4.48 min, 98.2% purity. N,N′-(1′,3′-Propylene)-bis-(-)-nor-MEP Hydrochloride (5b · 2HCl). (-)-nor-MEP 8 (1.54 g, 7.03 mmol), acetonitrile (15 mL), triethylamine (2.0 mL, 14.4 mmol), and 1,3-dibromopropane (0.357 mL, 3.52 mmol) were used to produce 5b (1.20 g, 71%). Subsequent salt formation of 5b (0.90 g) gave 5b · 2HCl (0.90 g, 87%): mp 165-168 °C; [R]D -48.38° (c 0.228, MeOH); IR ν 3176, 2935, 1599, 1447, 1229 cm-1 ; 1 H NMR (DMSO-d6) 10.18, 9.97 (br s, 6/5 H, NH+), 9.58, 9.52, 9.44, 9.42 (s, 2H, Ar-OH), 8.68, 8.59 (br s, 4/5 H, NH+), 7.20–7.13 (m, 2H, Ar-H), 6.90–6.65 (m, 6H, Ar-H), 3.92 (d, 4/5 H, J ) 14.5 Hz, N-CH2), 3.56 (m, 6/5 H, N-CH2), 3.44–3.21 (m, 10H, N-CH2), 2.40 (m, 2H, CH2), 2.10–1.50 (m, 16H, CH2), 0.50 (m, 6H, CH3); MS (ESI) [M + H]+ 479.4, [M + 2H]2+ 240.2. HRMS m/z calcd for C31H47N2O2 [M + H]+, 479.3632; found, 479.3641. HPLC: tR ) 7.00 min, 99.1% purity. N,N′-(1′,6′-Hexylene)-bis-(-)-nor-MEP Hydrochloride (5e · 2HCl). (-)-nor-MEP 8 (1.96 g, 8.95 mmol), acetonitrile (20 mL), triethylamine (2.5 mL, 18.0 mmol), and 1,6-dibromohexane (0.702 mL, 4.48 mmol) were used to produce 5e (0.96 g, 41%). Subsequent salt formation gave 5e · 2HCl (1.06 g, 97%): mp 135-138 °C; [R]D -47.8° (c 0.175, MeOH); IR ν 3414, 3176, 2938, 2876, 2732, 1600, 1585, 1447, 1269, 1232 cm–1; 1 H NMR (DMSO-d6) 10.05 (br s, 1/2 H, NH+), 9.80 (br s, 3/4 H, NH+), 9.56, 9.53, 9.44, 9.42 (s, 2H, Ar-OH), 8.43, 8.33 (br s, 3/4 H, NH+), 7.22–7.13 (m, 2H, Ar-H), 6.87–6.76 (m, 4H, Ar-H), 6.71–6.66 (m, 2H, Ar-H), 3.84 (m, 3/4 H, N-CH2), 3.55 (m, 5/4 H, N-CH2), 3.34–3.09 (m, 10H, N-CH2), 2.38 (m, H, CH2), 2.12–1.73 (m, 15H, CH2), 1.57–1.44 (m, 4H, CH2), 1.35–1.25 (m, 4H, CH2), 0.50 (t, 6H, J ) 7.4 Hz, CH3); MS (ESI) [M + H]+ 521.7, [M + 2H]2+ 261.4. HRMS m/z calcd for C34H53N2O2 [M + H]+, 521.4102; found, 521.4086. HPLC: tR ) 8.10 min, 97.6% purity. Table 2. Inhibition of AChE-Induced A
Aggregation by Bis-(-)-nor-MEPs 5g-i and Reference Compounds compd chain length (n) inhibition (%) at 100 µM inhibition (%) at 200 µM IC50 (µM) propidium iodine 85.6 ( 4.4 98.6 ( 5.9 12.8 ( 0.4 (-)-MEP nda 0 nda 5g 8 0 15.2 ( 0.2 nda 5h 9 90.8 ( 0.2 99.2 ( 0.1 16.6 ( 0.5 5i 10 95.8 ( 0.5 98.4 ( 0.1 5.8 ( 0.3 a nd: not determined. 2032 Journal of Medicinal Chemistry, 2008, Vol. 51, No. 7 Xie et al

Journal of Medicinal Chemistry, 2008, Vol. 51, No. 7 2033 NNN-(1, 7-Heptylenej-bis-(-)-nor-MEP Hydrochloride(5f. Subsequent salt for gave5j2HC1(0.47g,84%):m 2HCI).(-)-nor-MEP 8(1.70 g, 7.76 mmol), acetonitrile(20 mL) 108-112°C;[alb 0.29,MeOH);IRv3423,3180,2927 mL, 3.88 mmol)were used to produce 5f(0.73 g, 35%). Subsequent 10.13, 10.02(br s, 7/5 H, NH), 9.58, 9.55, 947, 9.45(s, 2H, salt formation gave 5f. 2HCI(0.70 g, 84%0): mp 125-128C; [alD Ar-OH, 8.41, 8.37(br s, 3/5H, NH), 7. 18-7.10(m, 2H, Ar-H), 429601801Rp34订2H0AOd)973522m6H,AB38(351HJ=141 Hz. N-C田H 1600,1585,1447,1268,1232cm H,J=13.7Hz,N-CH2),3.42-3.26(m,3H,N-CH2), brs,2/3H,NH),9.52,9.50,942,941(s,2H,Ar-OH,8.253.14-3.03(m,7H,N-CH2),2.37-232(m,H,CH2),2.10-1.97(m brs,4/3H,NH+),7.22-714(m,2H,Ar-H,687-666(m,6H,3H,CH2),1.82-1.70(m,12H,CH2),1.54-1.37(m,4H,CH2 413813341326:15且1+1+19mxAC1M图 CH2),2.13(m,4/5H,CH2),2.00-1.73(m,14H,CH2),1.53-1.4 591.4884: found,591.4901.HPLC:R=15.30min,98.9% purity m,4H,CH2),1.30(m,6H,CH2),0.50(m,6H,CH3);MS(ESD) N, N-(1, 12-Dodecydene)-bis-(-)-nor-MEP Hydrochloride M +H 535.8, [M 2H] 268.4. HRMS m/z calcd for (5k. 2HCI).(-)-nor-MEP 8(0.69 g, 3.15 mmol), acetonitrile(10 C3sHsN2O2[M+H+,535.4258; found,535.4258.HPC:R= mL), triethylamine(0.9 mL, 6.47 mmol), and 1, 12-dibromodode- 9.67 min, 99.4% purity cane(0.53 mL, 1.58 mmol) were used to produce 5k(0.34 g, 36%0) N,N-(1, 8-Octylene)-bis-(-j-nor-MEP Hydrochloride(5g 2HCI).(-)-nor-MEP 8(0.94 g, 4.29 mmol), acetonitrile(10 mL), 0105Cab3720300340292128 triethylamine(1. 2 mL, 8.63 mmol), and 1, 8-dibromooctane(0.40 mL, 2.15 mmol)were used to produce 5g(0.43 g, 37%) Subsequent NH,), 9.49, 9.48, 9.40(s, 2H, Ar-OH), 8.23(br s, 2/3 H, NH), salt formation of 5g(0.31 g) gave 5g 2HCI(0. 29 g, 83%0): mp 7 19-7.11(m, 2H, Ar-H), 6.85-6.64(m, 6H, Ar-H), 3.82(d, 4/5 101-106°C;alb-37.8°(c0.099,MeOH;IRv3420.2936,H,J=13.7Hz,N-CH2),3.53(d,6/5H,J=13.3H2,N-CH2), 1600,1447,1269cm-1;HNMR①DMSO-d6)10.11,9.95(brs,3.37-3.30(m,3HN-CH2),3.15-305(m,7HN-CH),236-231 43H,NH,9.57,9.54,9.45,9.43(s,2H,Ar-OH,8.43,8.35(m,H,CH2),2.10(m,HCH2),1.81-1.70(m,14H,CH2),152-1.42 brs,23H,NH),719-7.11(m,2H,Ar-H,6.85-664(m,6H (m,4H,CH2),1.27-1.24(m,16H,CH2),0.48(m,6H,CHy);Ms Ar-H),3.8l(d,2/3H,J=14.1Hz,N-CH2),3.53(d,4/3H,J (ESD[M+ H+ 605.3. HRMS m/z caled for CaoH6sN2O2[M 13.7Hz,N-CH2),3.35-3.28(m,3H,N-CH2),3.15-3.05(m,7H,H,605.5041; found,605.5054.HPLC:lg=19.73min,96.1% N-CH2),2.38-2.33(m,H,CH2),2.11-1.96(m,3H,CH2), punty 80-1.70(m,12H,CH2),1.51-1.4l(m,4H,CH2),1.28-1.24(m, General Procedure for the Synthesis of Intermediate Am- 8H, CH2), 0.47(t, 6H,J=7.4 Hz, CH3): MS(ESI)[M+ HI ide Compounds 9c, d. Triethylamine(2 equiv) was added to a 5494, [M+2H]275.2. HRMS m/z calcd for C36Hs7 IM+ solution of (-)-nor-MEP 8 in dry CH2Cl. Then a, o-alkanediacyl dihalide(0.5 equiv) in dry CH2Cl2 was added dropwise at 0 The mixture was stirred for 15 min at oC. The mixture was washed NNN-(1,9-Nonylene)-bis-(-)-nor-MEP Hydrochloride(5h. with H20 (5 mL), 2 M HCI(8 mL), and then H2o (5 mL). The 2HCI(-)-nor-MEP 8(0.89 g, 4.06 mmol), acetonitrile(10 mL), combined water layers were back-extracted with CH2C1z(10 mL triethylamine(1. 2 mL, 8.62 mmol), and 1, 9-dibromononane(0.42 x 3). All the CH2Cl2 layers were combined and dried with mL, 2.03 mmol) were used to produce 5h(0.71 g, 62%0) Subsequent anhydrous Na2SO4. Evaporation of the solvent under reduced salt formation of sh(0.67 g) gave 5h 2HCI(0.62 g, 82%o): mp pressure gave a yellowish foam. Purification by chromatography 118-124C; aI-3913( 0.32, MeOH); IR v 3423, 2934, 1600. on silica gel eluted with petroleum ether/EtOAc (1: 3) afforded the 1585,1446,1268cm-; H NMR(DMSO-d6)10.10,995brs, mide intermediates 9c.d as a white foan 43H,NH,9.56,9.54,9.44(s,2H,Ar-OH,8.41,8.34(brs, N, N-(1,, 4-Succinyl)-bis-(-j-nor-MEP (9c).(-)-nor-MEP 8 2/3H,NH,7.19-7.11(m,2H,Ar-H),6846.64(m,6H,Ar-H (1.45 g, 6.63 mmol), CH2Cl2(35 mL), triethylamine(1.84 mL. 12.2 3.82(d, 2/3 H, J= 14.1 Hz, N-CH2), 3.53(d, 4/3 H, J=13.7 mmol), and succinyl chloride(0.382 mL, 3.30 mmol) were used to Hz,N-CH2),3.38-3.27(m,3H,N-CH2),3.15-3.04m,阻H, produce 9e(0.73g,41%).IRv3170.2966,2936,1737,1614 N-CH2),2.38-2.32(m,H,CH2),2.10-2.01(m,3H,CH2),1596,145,1427,1266,1238,1202cm-1;HNMR(DMSO-d6) 1.79-1.70(m,12H,CH2),1.541.41(m,4H,CH2),1.29-1.27(m,8.79(s,2H,Ar-OH),7.19(t,2H,Ar-H),678-6.70(m,6H, 10H,CH2),O.47(t,6H,J=74Hz,CH);MS(ESD[M+HAr-H,4.88(d,2H,J=14.7Hz,N-CH2),3.59(d,2H,J1= 563.5, M+ 2H]- 282.3 HRMS m/z caled for C37HsgN2O M 117Hz,2=7.0Hz,N一CH2),3.08(d,2H,J=15.0Hz,N-CH2 H+,5634571; found,5634553.HPC:k=15.98min,98.4%21(t,2H,J=1.7Hz,CH2),283(d,2H,J=136Hz,N-CH2), 2.39(dm,2H,J=77Hz,N-CH2),2.33(d,2H,J=13.2Hz, N, N-(1, 10-Decylene-bis-(-)-nor-MEP Hydrochloride (5i N-CH2),1.82-1.48(m,14H,CH2),0.68(t,6H,J=73Hz,CH3); 2HCI(-)-nor-MEP 8(0.83 g, 3.78 mmol), acetonitrile(10 mL), MS (ESD)[M+ H 521.3 triethylamine(1. 1 mL, 7.91 mmol), and 1, 10-dibromodecane(043 NNN-(1, 5-Glutaryl)-bis-(-)-nor-MEP (9d).(-)-nor-MEP 8 mL, 1.89 mmol) were used to produce 5i(0.51 g, 47%) Subsequent (1.59 g, 7.26 mmol), CH2Cl>(35 mL), triethylamine(2.02 mL, 14.4 salt formation of 5i(0.47 g) gave 5i 2HCI(0.45 g, 85%): mp mmol), and glutaryl chloride(0.481 mL, 3.63 mmol) were used to 2856,2733,1600,1585,1447,1269,1230cm-; H NMR(DMSO-1443,1264cm-;HNMR(CDCl3)8.54,8.10,7.777.52brs d6)10.09,9.94(brs,4/3H,NH),9.57,9.54,946,945(s,2H,4,2H,Ar-OH,7.17(t,2H,Ar-H,7.05-693(m,2H,Ar-H Ar-OH,841,8.34(brs,2/3H,NH+),7.18-7.11(m,2H,Ar-H),6.82-6.70(m,4H,Ar-H,4.53(d,H,J=149Hz,N-CH2) 6846.64(m,6H,Ar-H),3.82(d,2/3H,J=14.5Hz,N-CH2),3.75-349(m,3H,N-CH2),3.41-3.18(m,2HN-CH2),299-294 3.52(d,4/3H,J=14.1Hz,N-CH2),3.36-3.27(m,3H,N一CH2),(m,H,N-CH2),2.54-2.46(m,H,N-CH2),2.34-2.17(m,4H, 3.14-3.03(m,7H,N-CH2),2.38-2.32(m,H,CH2),2.13-1.95(m,CO-CH2),1.93-1.50(m,18H,CH2),0.62-0.51(m,6H,CH3);MS H,CH2,1.79-1.70(m,12H,CH2),1.54-1.41(m,4H,CH2),( ESDM+H]+5353 1.28-1.25(m,12H,CH2),0.47(t,6H,J=7.0Hz,CH3);MS(ESD General Procedure for the Synthesis of Bis-(-)-nor-MEP [M H+ 577.5, [M 2H]2+ 289.3. HRMS m/z calcd for C Compounds 5e, d. A solution of ge, d in dry THF was added C3sH6IN202 [M+ H, 577.4728: found, 577. 4747. HPLC: IR dropwise to lithium aluminum hydride (5 equiv) in dry THF at 22 13 min, 98.9% purity room temperature. The mixture was refluxed for 1 h, and then H2O NNN-(1,11'-Undecydene)-bis-(-)-nor-MEP Hydrochloride 15% NaOH. and H,O were added. The mixture was stirred for 15 (5j 2HCI(-)-nor-MEP 8(0.78 g, 3.56 mmol), acetonitrile (10 min at room temperature. The mixture was filtered, and the solid mL), triethylamine(1.0 mL, 7.20 mmol), and 1, 1l-dibromounde- material was washed with THF. The combined THF solution was cane(0.418 mL, 1.78 mmol) were used to produce 5j(0.50 g, 48%0). evaporated to remove solvents. The residue was treated with H2O

N,N′-(1′,7′-Heptylene)-bis-(-)-nor-MEP Hydrochloride (5f· 2HCl). (-)-nor-MEP 8 (1.70 g, 7.76 mmol), acetonitrile (20 mL), triethylamine (2.2 mL, 15.8 mmol), and 1,7-dibromoheptane (0.674 mL, 3.88 mmol) were used to produce 5f (0.73 g, 35%). Subsequent salt formation gave 5f· 2HCl (0.70 g, 84%): mp 125-128 °C; [R]D -44.29° (c 0.218, MeOH); IR ν 3417, 3186, 2938, 2866, 2740, 1600, 1585, 1447, 1268, 1232 cm-1 ; 1 H NMR (DMSO-d6) 9.70 (br s, 2/3 H, NH+), 9.52, 9.50, 9.42, 9.41 (s, 2H, Ar-OH), 8.25 (br s, 4/3 H, NH+), 7.22–7.14 (m, 2H, Ar-H), 6.87–6.66 (m, 6H, Ar-H), 3.85 (d, 4/5 H, J ) 14.1 Hz, N-CH2), 3.56 (d, 6/5 H, J ) 14.1 Hz, N-CH2), 3.39–3.01 (m, 10H, N-CH2), 2.40 (m, 6/5 H, CH2), 2.13 (m, 4/5 H, CH2), 2.00–1.73 (m, 14H, CH2), 1.53–1.45 (m, 4H, CH2), 1.30 (m, 6H, CH2), 0.50 (m, 6H, CH3); MS (ESI) [M + H]+ 535.8, [M + 2H]2+ 268.4. HRMS m/z calcd for C35H55N2O2 [M + H]+, 535.4258; found, 535.4258. HPLC: tR ) 9.67 min, 99.4% purity. N,N′-(1′,8′-Octylene)-bis-(-)-nor-MEP Hydrochloride (5g · 2HCl). (-)-nor-MEP 8 (0.94 g, 4.29 mmol), acetonitrile (10 mL), triethylamine (1.2 mL, 8.63 mmol), and 1,8-dibromooctane (0.406 mL, 2.15 mmol) were used to produce 5g (0.43 g, 37%). Subsequent salt formation of 5g (0.31 g) gave 5g · 2HCl (0.29 g, 83%): mp 101-106 °C; [R]D -37.8 ° (c 0.099, MeOH); IR ν 3420, 2936, 1600, 1447, 1269 cm-1 ; 1 H NMR (DMSO-d6) 10.11, 9.95 (br s, 4/3 H, NH+), 9.57, 9.54, 9.45, 9.43 (s, 2H, Ar-OH), 8.43, 8.35 (br s, 2/3 H, NH+), 7.19–7.11 (m, 2H, Ar-H), 6.85–6.64 (m, 6H, Ar-H), 3.81 (d, 2/3 H, J ) 14.1 Hz, N-CH2), 3.53 (d, 4/3 H, J ) 13.7 Hz, N-CH2), 3.35–3.28 (m, 3H, N-CH2), 3.15–3.05 (m, 7H, N-CH2), 2.38–2.33 (m, H, CH2), 2.11–1.96 (m, 3H, CH2), 1.80–1.70 (m, 12H, CH2), 1.51–1.41 (m, 4H, CH2), 1.28–1.24 (m, 8H, CH2), 0.47 (t, 6H, J ) 7.4 Hz, CH3); MS (ESI) [M + H]+ 549.4, [M + 2H]2+ 275.2. HRMS m/z calcd for C36H57N2O2 [M + H]+, 549.4415; found, 549.4428. HPLC: tR ) 12.25 min, 97.9% purity. N,N′-(1′,9′-Nonylene)-bis-(-)-nor-MEP Hydrochloride (5h · 2HCl). (-)-nor-MEP 8 (0.89 g, 4.06 mmol), acetonitrile (10 mL), triethylamine (1.2 mL, 8.62 mmol), and 1,9-dibromononane (0.423 mL, 2.03 mmol) were used to produce 5h (0.71 g, 62%). Subsequent salt formation of 5h (0.67 g) gave 5h · 2HCl (0.62 g, 82%): mp 118-124 °C; [R]D -39.13° (c 0.32, MeOH); IR ν 3423, 2934, 1600, 1585, 1446, 1268 cm-1 ; 1 H NMR (DMSO-d6) 10.10, 9.95 (br s, 4/3 H, NH+), 9.56, 9.54, 9.44 (s, 2H, Ar-OH), 8.41, 8.34 (br s, 2/3 H, NH+), 7.19–7.11 (m, 2H, Ar-H), 6.84–6.64 (m, 6H, Ar-H), 3.82 (d, 2/3 H, J ) 14.1 Hz, N-CH2), 3.53 (d, 4/3 H, J ) 13.7 Hz, N-CH2), 3.38–3.27 (m, 3H, N-CH2), 3.15–3.04 (m, 7H, N-CH2), 2.38–2.32 (m, H, CH2), 2.10–2.01 (m, 3H, CH2), 1.79–1.70 (m, 12H, CH2), 1.54–1.41 (m, 4H, CH2), 1.29–1.27 (m, 10H, CH2), 0.47 (t, 6H, J ) 7.4 Hz, CH3); MS (ESI) [M + H]+ 563.5, [M + 2H]2+ 282.3. HRMS m/z calcd for C37H59N2O2 [M + H]+, 563.4571; found, 563.4553. HPLC: tR ) 15.98 min, 98.4% purity. N,N′-(1′,10′-Decylene)-bis-(-)-nor-MEP Hydrochloride (5i · 2HCl). (-)-nor-MEP 8 (0.83 g, 3.78 mmol), acetonitrile (10 mL), triethylamine (1.1 mL, 7.91 mmol), and 1,10-dibromodecane (0.438 mL, 1.89 mmol) were used to produce 5i (0.51 g, 47%). Subsequent salt formation of 5i (0.47 g) gave 5i · 2HCl (0.45 g, 85%): mp 104-108 °C; [R]D -38.43° (c 0.27, MeOH); IR ν 3417, 3176, 2932, 2856, 2733, 1600, 1585, 1447, 1269, 1230 cm-1 ; 1 H NMR (DMSO￾d6) 10.09, 9.94 (br s, 4/3 H, NH+), 9.57, 9.54, 9.46, 9.45 (s, 2H, Ar-OH), 8.41, 8.34 (br s, 2/3H, NH+), 7.18–7.11 (m, 2H, Ar-H), 6.84–6.64 (m, 6H, Ar-H), 3.82 (d, 2/3 H, J ) 14.5 Hz, N-CH2), 3.52 (d, 4/3 H, J ) 14.1 Hz, N-CH2), 3.36–3.27 (m, 3H, N-CH2), 3.14–3.03 (m, 7H, N-CH2), 2.38–2.32 (m, H, CH2), 2.13–1.95 (m, 3H, CH2), 1.79–1.70 (m, 12H, CH2), 1.54–1.41 (m, 4H, CH2), 1.28–1.25 (m, 12H, CH2), 0.47 (t, 6H, J ) 7.0 Hz, CH3); MS (ESI) [M + H]+ 577.5, [M + 2H]2+ 289.3. HRMS m/z calcd for C38H61N2O2 [M + H]+, 577.4728; found, 577.4747. HPLC: tR ) 22.13 min, 98.9% purity. N,N′-(1′,11′-Undecydene)-bis-(-)-nor-MEP Hydrochloride (5j· 2HCl). (-)-nor-MEP 8 (0.78 g, 3.56 mmol), acetonitrile (10 mL), triethylamine (1.0 mL, 7.20 mmol), and 1,11-dibromounde￾cane (0.418 mL, 1.78 mmol) were used to produce 5j (0.50 g, 48%). Subsequent salt formation gave 5j· 2HCl (0.47 g, 84%): mp 108-112 °C; [R]D -38.53° (c 0.29, MeOH); IR ν 3423, 3180, 2927, 2856, 1600, 1585, 1446, 1267, 1232 cm-1 ; 1 H NMR (DMSO-d6) 10.13, 10.02 (br s, 7/5 H, NH+), 9.58, 9.55, 9.47, 9.45 (s, 2H, Ar-OH), 8.41, 8.37 (br s, 3/5 H, NH+), 7.18–7.10 (m, 2H, Ar-H), 6.84–6.64 (m, 6H, Ar-H), 3.81 (d, 3/5 H, J ) 14.1 Hz, N-CH2), 3.52 (d, 7/5 H, J ) 13.7 Hz, N-CH2), 3.42–3.26 (m, 3H, N-CH2), 3.14–3.03 (m, 7H, N-CH2), 2.37–2.32 (m, H, CH2), 2.10–1.97 (m, 3H, CH2), 1.82–1.70 (m, 12H, CH2), 1.54–1.37 (m, 4H, CH2), 1.27–1.24(m, 14H, CH2), 0.47 (t, 6H, J ) 7.4 Hz, CH3); MS (ESI) [M + H]+ 591.3. HRMS m/z calcd for C39H63N2O2 [M + H]+, 591.4884; found, 591.4901. HPLC: tR ) 15.30 min, 98.9% purity. N,N′-(1′,12′-Dodecydene)-bis-(-)-nor-MEP Hydrochloride (5k · 2HCl). (-)-nor-MEP 8 (0.69 g, 3.15 mmol), acetonitrile (10 mL), triethylamine (0.9 mL, 6.47 mmol), and 1,12-dibromodode￾cane (0.53 mL, 1.58 mmol) were used to produce 5k (0.34 g, 36%). Salt formation of 5k (0.58 g) gave 5k · 2HCl (0.49 g, 80%): mp 100-105 °C; [R]D -35.77° (c 0.30, MeOH); IR ν 3419, 2927, 2855, 1600, 1585, 1446, 1269; 1 H NMR (DMSO-d6) 10.00 (br s, 4/3 H, NH+), 9.49, 9.48, 9.40 (s, 2H, Ar-OH), 8.23 (br s, 2/3 H, NH+), 7.19–7.11 (m, 2H, Ar-H), 6.85–6.64 (m, 6H, Ar-H), 3.82 (d, 4/5 H, J ) 13.7 Hz, N-CH2), 3.53 (d, 6/5 H, J ) 13.3 Hz, N-CH2), 3.37–3.30 (m, 3H, N-CH2), 3.15–3.05 (m, 7H, N-CH2), 2.36–2.31 (m, H, CH2), 2.10 (m, H, CH2), 1.81–1.70 (m, 14H, CH2), 1.52–1.42 (m, 4H, CH2), 1.27–1.24 (m, 16H, CH2), 0.48 (m, 6H, CH3); MS (ESI) [M + H]+ 605.3. HRMS m/z calcd for C40H65N2O2 [M + H]+, 605.5041; found, 605.5054. HPLC: tR ) 19.73 min, 96.1% purity. General Procedure for the Synthesis of Intermediate Am￾ide Compounds 9c,d. Triethylamine (2 equiv) was added to a solution of (-)-nor-MEP 8 in dry CH2Cl2. Then R,ω-alkanediacyl dihalide (0.5 equiv) in dry CH2Cl2 was added dropwise at 0 °C. The mixture was stirred for 15 min at 0 °C. The mixture was washed with H2O (5 mL), 2 M HCl (8 mL), and then H2O (5 mL). The combined water layers were back-extracted with CH2Cl2 (10 mL × 3). All the CH2Cl2 layers were combined and dried with anhydrous Na2SO4. Evaporation of the solvent under reduced pressure gave a yellowish foam. Purification by chromatography on silica gel eluted with petroleum ether/EtOAc (1:3) afforded the amide intermediates 9c,d as a white foam. N,N′-(1′,4′-Succinyl)-bis-(-)-nor-MEP (9c). (-)-nor-MEP 8 (1.45 g, 6.63 mmol), CH2Cl2 (35 mL), triethylamine (1.84 mL, 12.2 mmol), and succinyl chloride (0.382 mL, 3.30 mmol) were used to produce 9c (0.73 g, 41%). IR ν 3170, 2966, 2936, 1737, 1614, 1596, 1455, 1427, 1266, 1238, 1202 cm-1 ; 1 H NMR (DMSO-d6) 8.79 (s, 2H, Ar-OH), 7.19 (t, 2H, Ar-H), 6.78–6.70 (m, 6H, Ar-H), 4.88 (d, 2H, J ) 14.7 Hz, N-CH2), 3.59 (dd, 2H, J1 ) 11.7 Hz, J2 ) 7.0 Hz, N-CH2), 3.08 (d, 2H, J ) 15.0 Hz, N-CH2), 2.91 (t, 2H, J ) 11.7 Hz, CH2), 2.83 (d, 2H, J ) 13.6 Hz, N-CH2), 2.39 (dm, 2H, J ) 7.7 Hz, N-CH2), 2.33 (d, 2H, J ) 13.2 Hz, N-CH2), 1.82–1.48 (m, 14H, CH2), 0.68 (t, 6H, J ) 7.3 Hz, CH3); MS (ESI) [M + H]+ 521.3. N,N′-(1′,5′-Glutaryl)-bis-(-)-nor-MEP (9d). (-)-nor-MEP 8 (1.59 g, 7.26 mmol), CH2Cl2 (35 mL), triethylamine (2.02 mL, 14.4 mmol), and glutaryl chloride (0.481 mL, 3.63 mmol) were used to produce 9d (0.74 g, 38%). IR ν 3383, 2933, 2877, 1616, 1583, 1443, 1264 cm-1 ; 1 H NMR (CDCl3) 8.54, 8.10, 7.77, 7.52 (brs × 4, 2H, Ar-OH), 7.17 (t, 2H, Ar-H), 7.05–6.93 (m, 2H, Ar-H), 6.82–6.70 (m, 4H, Ar-H), 4.53 (d, H, J ) 14.9 Hz, N-CH2), 3.75–3.49 (m, 3H, N-CH2), 3.41–3.18 (m, 2H, N-CH2), 2.99–2.94 (m, H, N-CH2), 2.54–2.46 (m, H, N-CH2), 2.34–2.17 (m, 4H, CO-CH2), 1.93–1.50 (m, 18H, CH2), 0.62–0.51 (m, 6H, CH3); MS (ESI) [M + H]+ 535.3. General Procedure for the Synthesis of Bis-(-)-nor-MEP Compounds 5c,d. A solution of 9c,d in dry THF was added dropwise to lithium aluminum hydride (5 equiv) in dry THF at room temperature. The mixture was refluxed for 1 h, and then H2O, 15% NaOH, and H2O were added. The mixture was stirred for 15 min at room temperature. The mixture was filtered, and the solid material was washed with THF. The combined THF solution was evaporated to remove solvents. The residue was treated with H2O Bis-(-)-nor-meptazinols as Inhibitors Journal of Medicinal Chemistry, 2008, Vol. 51, No. 7 2033

2034 Journal of Medicinal Chemistry, 2008, VoL. 51, No. 7 Xie et al (15 mL), drops of aqueous ammonia were added to adjust the ph ligand. The final conformation of the ligand was obtained after to 9, and the residue was extracted with CHCl3(20 mL x 3) 000 steps of energy minimization using the Tripos force field. The combined CHCl3 was dried with anhydrous Na2SO4 and Molecular docking was carried out using GOLD 3.0(CCDC graphed on silica gel and eluted with MeOH/CHCl3(0.5: 9.5)to conformations for the ligand. The active site was defined as all rovide 5c, d as an oil. Addition of dry HCl-ether to the solution atoms within a radius of 25 A around some specific residue atoms of 5c, d in dry ether, with pH adjusted to 3-4, gave the final OH of Tyr337 for mAChE and N2 of His438 for hBChE. We chose salt 5c, d' 2HCI as a powder more enlarged binding pockets here, concerned that smaller sites AN -(- e -b is- --n or- MlEP H drochloride:i e. catalytic and peripheral sites of AchE. The 600 genetic algorithm hydride(0. 20 g, 5.26 mmol), THF (30 mL), H2O(0.20 mL), 15% (GA)runs instead of the default 10 were erformed owing to the NaOH(0.20 mL), and H20 (0.60 mL)were used to produce 5c high flexibility of the ligand possessing a great many rotatable (0. 19 g, 36%0) Subsequent salt formation gave 5c. 2HCI(0.12 bonds. For each GA run, the default GA settings were used except 55%):mpl10-115°C;alb-51.96°(c0.092,MeOH);IR for the prohibited early termination and the permitted pyramidal 3254,2936,1600,1586,1448,1268cm-;HNMR(DMSO nitrogen inversion. d6)998,977(brs,4/3H,NH),9.56,9.54,9.43,9.42(s,2H Advanced combination approach of clustering and consensus Ar-OH).8.46(brs,2/3H,NH+),7.21-7.13(m,2H,Ar-H) scoring was used to guide the selection of the most reliable 685-665(m,6H,Ar-H),3.83(m,~2/3H,N-CH2),3.52(m, information from among a set of candidate conformations that 04/3 H. N-CH,). 3.36-3. 15(m, 10H. N-CH-)2.38(m, H. GOLD generated. All conformations were evaluated with four CH,). 2. 10-1.46(m, 19H. CH,0.49(t 6H, J=7.0 Hz, CH) available scoring functions, including three scoring functions MS(ESD)[M +H]+493.3, [M+2H)2+ 247.2 HRMS m/z caled (G-Score, D_Score, and ChemScore) from the CSCORE38module IR=7.45 min, 98.0% purity 1.2.1.The"rank-by-rank" "strategy reported by Wang et al. was NNN-(1,5-Pentylene)-bis-(-)-nor- MEP Hydrochloride (50 adopted to make consensus scoring. The final rank of a certain conformation was its average rank received from all four 2HCI). Compound 9d(0.55 g, 1.03 mmol), lithium aluminum functions. GOLD generated clusters based on different rmsd(root hydride(0.20 g, 5.26 mmol), THF (30 mL), H20(0.20 mL), 15% mean square deviation)criteria. A proper rmsd standard of clustering aOH(0.20 mL), and H20(0.60 mL) were used to produce 5d was important to the selection of representative clusters. Herein, (0.16 g, 31%. Subsequent salt formation of 5d( 0.10 g) gave rmsd values of 2.55 and 2.40 A were chosen as the criteria to cluster d·2HC1(0.06g,52%):mp80-82C;[alb-48.10°(c0.08 the docked conformations with mAChE and hBChE, respectively MeOH;IRv3417,2937,1600,1585,1447,1268cm-1;HNMR DMSO-d6)996,9.75(brs,5/4H,NH),9.57,9.52,9.44,9.42 Among the top 10 clusters for each ChE, the one with members possessing the minimum average"rerank" was identified as the (s,2H,Ar-OH,8.34(brs,3/4H,NH),7.19-7.12(m,2H representative cluster. The top"reranked"conformation in the (m, 5/4 H, N-CH2) 3.34-3.06('m, OH, N-CH2) 2.37( m, H. mode for the gander was selected as the representauve binding CH2),2.10-1.21(m,21H,CH2),0.48(m,6H,cHy);Ms(ESD)[M Inhibition of AChE-lnduced Ap Aggregation. Aliquots of 2 H 507.3,[M+ 2H2542 HRMS m/z caled for C33HsI N2O2 HL AB(1-40) peptide(Biosource), lyophilized from 2 mg/mL HFIP IM+H+,507.3945; found,507.3961.HPLC:lg=777min, solution and dissolved in DMSO, were incubated for 48 h at room temperature in 0.215 M sodium phosphate buffer(pH 8.0)at a final In Vitro AChE/BChE Inhibition Assay. Inhibitory activit concentration of 230 uM. For coincubation experiments, aliquots against AChE was evaluated by a modified Ellman's method. (16 AL) of human recombinant AChE (Sigma-Aldrich)(final Mice brain homogenate prepared in saline was used as a source of concentration of 2.3 uM, AB/AChE molar ratio of 100: 1)and AChE AChE; mice serum was the source of BChE. The AChE activity in the presence of 2 uL of the tested inhibitors were added. Blanks vas determined in a reaction mixture containing 200 uL of containing Af nd AB plus inhibitors at various concentra- solution of AChE(0.415 U/mL in 0. 1 M phosphate buffer, pH8.0), tions in 0.215 M sodium phosphate buffer(pH8.0)were prepared. 300 uL of a solution of 5, 5-dithio-bis(2-nitrobenzoic)acid(3.3 The final volume of each vial was 20 AL. Each assay was run in mM DTNB in 0.1 M phosphate buffered solution, pH 7.0, duplicate. Inhibitor stock solutions were prepared (c= 10 mM) containing NaHCO 6 mM), and 30 uL of a solution of the inhibitor and diluted in 0.215 M sodium phosphate buffer(pH 8.0)when (six to seven concentrations). After incubation for 20 min at 37 used. To quantify amyloid fibril formation, the thioflavin T oC, acetylthiocholine iodide(300 uL of 0.05 mM water solution) fluorescence method was then applied. 20 was added as the substrate, and AChe activity was determined by After incubation, the samples containing AB, AB plus AChE,or UV spectrophotometry from the absorbance changes at 412 nm fo AB plus AChE in the presence of inhibitors were diluted with 50 3 min at 25"C. The concentration of compound that produced 50% mM glycine-NaOH buffer(pH 8.5)containing 1.5 uM thioflavin inhibition of the AChE activity (ICso) was calculated by nonlinear T (Sigma-Aldrich) to a final volume of 2.0 mL. Fluorescence was regression of the response-concentration (log) curve. BChE monitored by PE LS45, with excitation at 446 nm and emission at inhibitory activity determinations were similarly carried out usin 490 nm. A time scan of fluorescence was performed, and the butyrylthiocholine iodide(0.05 mM)as the substrate. Results are intensity values reached at the plateau(around 300 s)were averaged reported as the mean+ SEM of ICso obtained from at least three after subtracting the background fluorescence from 1.5 uM thiola- vin T and AChE. The percent inhibition of the AChE-induced Molecular Docking. Molecular simulations were performed on aggregation due to the presence of increasing concentrations of the an R14000 SGI Fuel workstation with software package SYBYL inhibitor was calculated by the following expression: 100-(IF/ 6.9(Tripos Inc, St Louis, MO). Standard parameters were used IFo x 100), where IFi and IFo were the fluorescence intensities nless otherwise indicated. The X-ray crystallographic structures obtained of the mAChE complex with succinylcholine(PDB code 2HA2) inhibitor, respectively, after subtracting the fluorescence of respec and the native hBChE(IPoD)were retrieved from PDB. Het- tive blanks. Inhibition curves and linear regression parameters wer eroatoms and water molecules in the PDb files were removed obtained for each compound, and the ICso was extrapolated, when and all hydrogen atoms were subsequently added to the protein 3D coordinates of the ligand were generated by CORINA 3.0 MTT Assay of Cell Viability. The human neuroblastoma cell Molecular Networks GmbH, Erlangen, Germany, 2004).35Two ure Collection) cells were spN atoms were both protonated, and the Gasteiger-Huckel cultured in MEM/F-12(1: 1) (Invitrogen, Grand Island. partial charges 6, 37 were assigned to each atom of the resultant NY) supplemented with 10%o fetal calf serum(FCS, Invitrogen)

(15 mL), drops of aqueous ammonia were added to adjust the pH to 9, and the residue was extracted with CHCl3 (20 mL × 3). The combined CHCl3 was dried with anhydrous Na2SO4 and concentrated in vacuo to give a residue, which was chromato￾graphed on silica gel and eluted with MeOH/CHCl3 (0.5:9.5) to provide 5c,d as an oil. Addition of dry HCl-ether to the solution of 5c,d in dry ether, with pH adjusted to 3-4, gave the final salt 5c,d · 2HCl as a powder. N,N′-(1′,4′-Butylene)-bis-(-)-nor-MEP Hydrochloride (5c · 2HCl). Compound 9c (0.56 g, 1.08 mmol), lithium aluminum hydride (0.20 g, 5.26 mmol), THF (30 mL), H2O (0.20 mL), 15% NaOH (0.20 mL), and H2O (0.60 mL) were used to produce 5c (0.19 g, 36%). Subsequent salt formation gave 5c · 2HCl (0.12 g, 55%): mp 110-115 °C; [R]D -51.96° (c 0.092, MeOH); IR ν 3254, 2936, 1600, 1586, 1448, 1268 cm-1 ; 1 H NMR (DMSO￾d6) 9.98, 9.77 (br s, 4/3 H, NH+), 9.56, 9.54, 9.43, 9.42 (s, 2H, Ar-OH), 8.46 (br s, 2/3 H, NH+), 7.21–7.13 (m, 2H, Ar-H), 6.85–6.65 (m, 6H, Ar-H), 3.83 (m, ∼2/3 H, N-CH2), 3.52 (m, ∼4/3 H, N-CH2), 3.36–3.15 (m, 10H, N-CH2), 2.38 (m, H, CH2), 2.10–1.46 (m, 19H, CH2), 0.49 (t, 6H, J ) 7.0 Hz, CH3); MS (ESI) [M + H]+ 493.3, [M + 2H]2+ 247.2. HRMS m/z calcd for C32H49N2O2 [M + H]+, 493.3791; found, 493.3789. HPLC: tR ) 7.45 min, 98.0% purity. N,N′-(1′,5′-Pentylene)-bis-(-)-nor-MEP Hydrochloride (5d · 2HCl). Compound 9d (0.55 g, 1.03 mmol), lithium aluminum hydride (0.20 g, 5.26 mmol), THF (30 mL), H2O (0.20 mL), 15% NaOH (0.20 mL), and H2O (0.60 mL) were used to produce 5d (0.16 g, 31%). Subsequent salt formation of 5d (0.10 g) gave 5d · 2HCl (0.06 g, 52%): mp 80-82 °C; [R]D -48.10° (c 0.084, MeOH); IR ν 3417, 2937, 1600, 1585, 1447, 1268 cm-1 ; 1 H NMR (DMSO-d6) 9.96, 9.75 (br s, 5/4 H, NH+), 9.57, 9.52, 9.44, 9.42 (s, 2H, Ar-OH), 8.34 (br s, 3/4 H, NH+), 7.19–7.12 (m, 2H, Ar-H), 6.83–6.64 (m, 6H, Ar-H), 3.82 (m, 3/4 H, N-CH2), 3.52 (m, 5/4 H, N-CH2), 3.34–3.06 (m, 10H, N-CH2), 2.37 (m, H, CH2), 2.10–1.21 (m, 21H, CH2), 0.48 (m, 6H, CH3); MS (ESI) [M + H]+ 507.3, [M + 2H]2+ 254.2. HRMS m/z calcd for C33H51N2O2 [M + H]+, 507.3945; found, 507.3961. HPLC: tR ) 7.77 min, 96.1% purity. In Vitro AChE/BChE Inhibition Assay. Inhibitory activity against AChE was evaluated by a modified Ellman’s method.34 Mice brain homogenate prepared in saline was used as a source of AChE; mice serum was the source of BChE. The AChE activity was determined in a reaction mixture containing 200 µL of a solution of AChE (0.415 U/mL in 0.1 M phosphate buffer, pH 8.0), 300 µL of a solution of 5,5′-dithio-bis(2-nitrobenzoic) acid (3.3 mM DTNB in 0.1 M phosphate buffered solution, pH 7.0, containing NaHCO3 6 mM), and 30 µL of a solution of the inhibitor (six to seven concentrations). After incubation for 20 min at 37 °C, acetylthiocholine iodide (300 µL of 0.05 mM water solution) was added as the substrate, and AChE activity was determined by UV spectrophotometry from the absorbance changes at 412 nm for 3 min at 25 °C. The concentration of compound that produced 50% inhibition of the AChE activity (IC50) was calculated by nonlinear regression of the response-concentration (log) curve. BChE inhibitory activity determinations were similarly carried out using butyrylthiocholine iodide (0.05 mM) as the substrate. Results are reported as the mean ( SEM of IC50 obtained from at least three independent measures. Molecular Docking. Molecular simulations were performed on an R14000 SGI Fuel workstation with software package SYBYL 6.9 (Tripos Inc., St. Louis, MO). Standard parameters were used unless otherwise indicated. The X-ray crystallographic structures of the mAChE complex with succinylcholine (PDB code 2HA2)32 and the native hBChE (1P0I)28were retrieved from PDB. Het￾eroatoms and water molecules in the PDB files were removed, and all hydrogen atoms were subsequently added to the protein. 3D coordinates of the ligand were generated by CORINA 3.0 (Molecular Networks GmbH, Erlangen, Germany, 2004).35 Two sp3 N atoms were both protonated, and the Gasteiger-Huckel partial charges36,37 were assigned to each atom of the resultant ligand. The final conformation of the ligand was obtained after 1000 steps of energy minimization using the Tripos force field. Molecular docking was carried out using GOLD 3.0 (CCDC, Cambridge, U.K., 2005)33 to generate an ensemble of docked conformations for the ligand. The active site was defined as all atoms within a radius of 25 Å around some specific residue atoms: OH of Tyr337 for mAChE and N
2 of His438 for hBChE. We chose more enlarged binding pockets here, concerned that smaller sites might neither accommodate a large bis-ligand nor include both the catalytic and peripheral sites of AChE. The 600 genetic algorithm (GA) runs instead of the default 10 were performed owing to the high flexibility of the ligand possessing a great many rotatable bonds. For each GA run, the default GA settings were used except for the prohibited early termination and the permitted pyramidal nitrogen inversion. Advanced combination approach of clustering and consensus scoring was used to guide the selection of the most reliable conformation from among a set of candidate conformations that GOLD generated. All conformations were evaluated with four available scoring functions, including three scoring functions (G_Score, D_Score, and ChemScore) from the CSCORE38 module in SYBYL and another stand-alone scoring function, X-SCORE 1.2.1.39 The “rank-by-rank” strategy reported by Wang et al.40 was adopted to make consensus scoring. The final rank of a certain conformation was its average rank received from all four scoring functions. GOLD generated clusters based on different rmsd (root mean square deviation) criteria. A proper rmsd standard of clustering was important to the selection of representative clusters. Herein, rmsd values of 2.55 and 2.40 Å were chosen as the criteria to cluster the docked conformations with mAChE and hBChE, respectively. Among the top 10 clusters for each ChE, the one with members possessing the minimum average “rerank” was identified as the representative cluster. The top “reranked” conformation in the representative cluster was selected as the representative binding mode for the ligand. Inhibition of AChE-Induced A
Aggregation. Aliquots of 2 µL A
(1–40) peptide (Biosource), lyophilized from 2 mg/mL HFIP solution and dissolved in DMSO, were incubated for 48 h at room temperature in 0.215 M sodium phosphate buffer (pH 8.0) at a final concentration of 230 µM. For coincubation experiments, aliquots (16 µL) of human recombinant AChE (Sigma-Aldrich) (final concentration of 2.3 µM, A
/AChE molar ratio of 100:1) and AChE in the presence of 2 µL of the tested inhibitors were added. Blanks containing A
, AChE, and A
plus inhibitors at various concentra￾tions in 0.215 M sodium phosphate buffer (pH 8.0) were prepared. The final volume of each vial was 20 µL. Each assay was run in duplicate. Inhibitor stock solutions were prepared (c ) 10 mM) and diluted in 0.215 M sodium phosphate buffer (pH 8.0) when used. To quantify amyloid fibril formation, the thioflavin T fluorescence method was then applied.20 After incubation, the samples containing A
, A
plus AChE, or A
plus AChE in the presence of inhibitors were diluted with 50 mM glycine-NaOH buffer (pH 8.5) containing 1.5 µM thioflavin T (Sigma-Aldrich) to a final volume of 2.0 mL. Fluorescence was monitored by PE LS45, with excitation at 446 nm and emission at 490 nm. A time scan of fluorescence was performed, and the intensity values reached at the plateau (around 300 s) were averaged after subtracting the background fluorescence from 1.5 µM thiofla￾vin T and AChE. The percent inhibition of the AChE-induced aggregation due to the presence of increasing concentrations of the inhibitor was calculated by the following expression: 100 - (IFi/ IFo × 100), where IFi and IFo were the fluorescence intensities obtained for A
plus AChE in the presence and in the absence of inhibitor, respectively, after subtracting the fluorescence of respec￾tive blanks. Inhibition curves and linear regression parameters were obtained for each compound, and the IC50 was extrapolated, when possible. MTT Assay of Cell Viability. The human neuroblastoma cell line SH-SY5Y (American Type Culture Collection) cells were cultured in MEM/F-12 (1:1) medium (Invitrogen, Grand Island, NY) supplemented with 10% fetal calf serum (FCS, Invitrogen), 2034 Journal of Medicinal Chemistry, 2008, Vol. 51, No. 7 Xie et al

alanthamine and galanthamine-galanthaminium salts. Bioorg. Med. hem.Le.2000,10,637-639 10 cells/well (200 ul) into 96-well plates and allowed to adhere (11) Carlier, P. R. Du, D. M.: Han, Y. F. Liu, J Perola, E; W and grow. When cells reached the required confluence, they were L. D ; Pang. Y. P. Dimerization of an inactive fragment of huperzine laced into serum-free medium and treated with the synthesized A produce a drug with twice the potency of the natural product Chem,lnt.Ed.2000,39,1775-1777 compounds 5h and 5i. Twenty-four hours later the surv ( 12)Feng, S; Wang. Z; He, X; Zheng, S: Xia, Y. Jiang, H; Tang, X: as determined by MTT assay. Briefly, after incubat Bai, D. Bis-huperzine B: highly potent ar L of MTT(5 mg/mL: Sigma, St Louis, MO)at 37 erase inhibitors. J Med. Chem. 2005. 48. 655-657 living cells containing MTT formazon crystals were (13)Munoz-Torrero, D: Camps, P. Dimeric and hybrid anti-Alzheime in 200 uL of dimethyl sulfoxide(DMsO, Sigma). The absor- drug candidates. Curr. Med. Chem. 2006. 13. 399-422 ance of each well was measured using a microculture plate (14)Harel, M. Schalk, L; Ehret-Sabatier, L; Bouet, F. Goeldner. M. HirtI reader with a test wavelength of 570 nm and a reference C ; Axelsen, P H. Silman, L; Sussman, J. L. Quatemary ligand binding Proc. Natl. Acad. Sci. U.S.A. 1993. 90. 9031-9035 Acknowledgment. We thank the National Natural Science (15)Li, W: Hao, J; Tang, Y; Chen, Y; Qiu, Z Comparative studies of Foundation of China(Grants 30472088, 30772553, and cophore. Acta. Pharmacol Sin. 2005, 26, 334-338 30371731), the Program of Shanghai Subject Chief Scientist (16)Ennis, C. Haroun, F. and Lattimer, N. Can the effects of meptazinol Grant 06XD14011), and the Major Basic Research Project of aceyl guinea-pig isolated ileum be explained by inhibition of Shanghai Municipal Science and Technology Commission (17) Chen, Y Studies on the Synthesis, Resolution and Optical Isomers (Grant 07DJ14005) for financial support. We also gratefully Meptazinol. Ph. D. Dissertation, Fudan University, Shanghai, P. R thank Dr Manuela Bartolini(University of Bologna, Italy) and China. 2004 Dr. Margarita Dinamarca(Pontificia Universidad Catolica, ( 18)Xie, Q: Tang, Yun ; Li, w: Wang, X; Qiu, Z Investigation of the Chile) for their valuable suggestions in the experiments on binding mode of (-)-meptazinol and bis-meptazinol derivatives on acetylcholinesterase using a molecular docking method. J Mol Model. AChE-induced AB aggregation. 2006.12,390-397 (19) Savin Note Added after ASAP Publication. This manuscript was Chiasserini. L: Pellerano. C: Novellino. E: Mckissic. D: Saxena released ASAP on March 12, 2008 with errors in the Experimental and Acknowledgment Sections. The correct version posted recognition sites. Rational design of novel, selective, and highly potent March 15. 2008 cholinesterase inhibitors. Med. Chem. 2003. 46.1-4 (20) Bartolini, M: Bertucci, C. Cavrini, V: Andrisano, V. B-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies References Biochem. Pharmacol. 2003. 65 407-410 (1)Walsh, D. M ; Selkoe, DJ the molecular basis of memory (21)St dicarboxylic acid esters as 2004,44,181-193 dealkylating agents J. Org. Chem. 1973, 18, 1652-1657 (2)Dekosky, S. T Pathology ys of Alzheimers disease with (22) Pecherer, B. Stumpf, J; Brossi, A. Synthesis and characteristics of n update on new developments in treatment. J. Am. Geriatr. Soc. various 3-benzazocines, a class of potential analgesics. Helv. Chim. 2003 Acta1970,53,763-770. German) ()Bartus, R. T; Dean, R. L; Beer, B: Lippa, A.S. The cholinergic (23)Hobson, J. D. McCluskey, J. G Cleavage of tertiary bases with phenyl pothesis of geriatric memory dysfunction. Science 1982, 217, 408- chloroformate: the reconversion of 21-deoxyajmaline into ajmaline J.Chem.Soc.C1967,2015-2017 (4)Soreq, H: Seidman, S. Acetylcholinesterases-new roles for an old (24) Abdel-Monem, M. M; Pe se, P. S. N-Demethyla morphine and structurally related compounds with chloroformate (5)Alvar Bronfman. F. Perez. C. A: Vicente, M: Garrido, J. esters. J. Med. Chem. 1972. 15. 208-210 (25)Lu, M. Design and Synthesis of Meptazinol Prodrug and Bivalent Ph.D. Dissertation, Fudan University, Shang P. R. China. 2005 Opazo, C: Alarcon, R: Garrido, J. Inestrosa, N. C. (26)Li. w: Wang, X. Lau, C ; Tang. Y. Xie. Q: Qiu, Z Conformational Acetylcholinesterase promotes the re-analysis of(+)-meptazinol: an opioid with mixed analgesic phar. by forming a complex with the growing fibrils. J. Mol. Biol Pharmacol. Sin. 2006. 27 (27)Decker, M. Krauth, F: Lehmann, J. Novel tricyclic quinazolinimines (7)De Ferran, G. V. Canales. M. A. Shin. I Weiner, L. M.: Silman, L. and related tetracyclic nitrogen bridgehead compounds as cholines Inestrosa, N. C. A structural motif of acetylcholinesterase that promotes inhibitors with selectivity towards butyrylcholinesterase. Bioorg loid beta-peptide fibril formation. Biochemistry 2001, 40, 10447 Med.Chem.2006,14,1966-1977 ( 8)Inestrosa N. C: Alvarez. A: Perez. C. A: Moreno, R. D (28)Nicolet, Y: Lockridge, O; Masson, P: Fontecilla-Camps, J. C, M: Linker, C; Casanueva, O. L; Soto, C: Garrido, J. Acetylcho Nachon, F Crystal structure of human butyrylcholinesterase and inesterase accelerates assembly of amyloid-B-peptides into Alzhe. its complexes with substrate and products. J. Biol. Che. 2003, 278, 41141-41147. imer's fibrils: possible role of the peripheral site of the enzyme. Neuron (29) Harel, M. Sussman, J. L: Krejci, E: Bon, S: Chanal, P; Massoulio 9)(a) Pang. Y.P. Quiram, P; Jelacic, T Hong, F Brimijoin, S. Highly J; Silman, I. Conversion of acetylcholine potent, selective and low cost bis-tetrahydroaminacrine inhibitors of erase: modeling and mutagenesis bioche 2,89,10827-10 (0)Greig. N. H; Lahiri, D. K: Sambamurti, K. Butyrylcholinesterase isease. J. BioL. Chem. 1996. 271. 23646-23649.(b)Carlier, P. R important new target in Alzheimers disease therapy. Int. Psycho. natr.2002,l4( Suppl.1).77-91 Wong H.S. Pang. Y.P. Evaluation of short-tether bis- THA AChE (31)Birks, J; Grimley Evans, J. lakovidou, V: Tsolaki, M Rivastigmine inhibitors. A further test of the dual binding site hypothesis. Bioorg Med. Chem. 1999, 7, 351-357.(c)Rydberg, E H; Brumshtein, B. CD001191 Greenblatt, H. M.: Wong. D. M.: Shaya. D. Williams, L. D. Carlier (32)Bourne, Y. Radic, Z; Sulzenbacher, G ; Kim, E: Taylor, P; Marchot P Substrate and produ ing through the active center gorge binding of bis(5 )-tacrine produces a dramatic rearrangement in the binding. J. Biol. Che. 2006. 281, 29256-29267 active-site gorge. J. Med. Chen. 2006. 49, 5491-5500 (3)Jones, G: Willett, P. Glen, R. C. Leach, A. R: Taylor, R. (10)(a)Mary, A: Renko, D. Z: Guillou, C; Thal, C Potent acetylche inesterase inhibitors: design, synthesis, and structure-activity relation ships of bis-interacting ligands in the galanthamine series. Bioorg. Mec c Mol. Biol. 1997, 267.o of a genetic algorithm for flexible docking ao. Chem. 1998. 6, 1835-1850.(b)Guillou, C: Mary, A Renko, D Z Dong, C. Z; Heymans, F; Chen, H. Z Pharma Gras, E: Thal, C. Potent acetylcholinesterase inhibitors: des PMS777, a new AChE inhibitor with PAF antago ynthesis and structure-activity relationships of alkylene linked bis- J. Neuropsychopharmacol. 2007, 10, 21-2

100 U/mL penicillin, and 100 µg/mL streptomycin in a humidified atmosphere containing 5% CO2 at 37 °C. Cells were plated at 5 × 104 cells/well (200 µl) into 96-well plates and allowed to adhere and grow. When cells reached the required confluence, they were placed into serum-free medium and treated with the synthesized compounds 5h and 5i. Twenty-four hours later the survival of cells was determined by MTT assay. Briefly, after incubation with 20 µL of MTT (5 mg/mL; Sigma, St. Louis, MO) at 37 °C for 3 h, living cells containing MTT formazon crystals were solubilized in 200 µL of dimethyl sulfoxide (DMSO, Sigma). The absor￾bance of each well was measured using a microculture plate reader with a test wavelength of 570 nm and a reference wavelength of 655 nm. Acknowledgment. We thank the National Natural Science Foundation of China (Grants 30472088, 30772553, and 30371731), the Program of Shanghai Subject Chief Scientist (Grant 06XD14011), and the Major Basic Research Project of Shanghai Municipal Science and Technology Commission (Grant 07DJ14005) for financial support. We also gratefully thank Dr. Manuela Bartolini (University of Bologna, Italy) and Dr. Margarita Dinamarca (Pontificia Universidad Católica, Chile) for their valuable suggestions in the experiments on AChE-induced A
aggregation. Note Added after ASAP Publication. This manuscript was released ASAP on March 12, 2008 with errors in the Experimental and Acknowledgment Sections. The correct version posted on March 15, 2008. References (1) Walsh, D. M.; Selkoe, D. J. Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron 2004, 44, 181–193. (2) Dekosky, S. T. Pathology and pathways of Alzheimer’s disease with an update on new developments in treatment. J. Am. Geriatr. Soc. 2003, 51, 314–320. (3) Bartus, R. T.; Dean, R. L.; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408– 414. (4) Soreq, H.; Seidman, S. Acetylcholinesterasessnew roles for an old actor. Nat. ReV. Neurosci. 2001, 2, 294–302. (5) Alvarez, A.; Bronfman, F.; Pérez, C. A.; Vicente, M.; Garrido, J.; Inestrosa, N. C. Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-beta-peptides. Neurosci. Lett. 1995, 201, 49–52. (6) Alvarez, A.; Opazo, C.; Alarcón, R.; Garrido, J.; Inestrosa, N. C. Acetylcholinesterase promotes the aggregation of amyloid-
-peptide fragments by forming a complex with the growing fibrils. J. Mol. Biol. 1997, 272, 348–361. (7) De Ferrari, G. V.; Canales, M. A.; Shin, I.; Weiner, L. M.; Silman, I.; Inestrosa, N. C. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 2001, 40, 10447– 10457. (8) Inestrosa, N. C.; Alvarez, A.; Pérez, C. A.; Moreno, R. D.; Vicente, M.; Linker, C.; Casanueva, O. I.; Soto, C.; Garrido, J. Acetylcho￾linesterase accelerates assembly of amyloid-
-peptides into Alzhe￾imer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 1996, 16, 881–891. (9) (a) Pang, Y. P.; Quiram, P.; Jelacic, T.; Hong, F.; Brimijoin, S. Highly potent, selective and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase: steps toward novel drugs for treating Alzheimer’s disease. J. Biol. Chem. 1996, 271, 23646–23649. (b) Carlier, P. R.; Han, Y. F.; Chow, E. S. H.; Li, C. P. L.; Wang, H.; Lieu, T. X.; Wong, H. S.; Pang, Y. P. Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. Bioorg. Med. Chem. 1999, 7, 351–357. (c) Rydberg, E. H.; Brumshtein, B.; Greenblatt, H. M.; Wong, D. M.; Shaya, D.; Williams, L. D.; Carlier, P. R.; Pang, Y. P.; Silman, I.; Sussman, J. L. Complexes of alkylene￾linked tacrine dimers with Torpedo californica acetylcholinesterase: binding of bis(5)-tacrine produces a dramatic rearrangement in the active-site gorge. J. Med. Chem. 2006, 49, 5491–5500. (10) (a) Mary, A.; Renko, D. Z.; Guillou, C.; Thal, C. Potent acetylcho￾linesterase inhibitors: design, synthesis, and structure-activity relation￾ships of bis-interacting ligands in the galanthamine series. Bioorg. Med. Chem. 1998, 6, 1835–1850. (b) Guillou, C.; Mary, A.; Renko, D. Z.; Gras, E.; Thal, C. Potent acetylcholinesterase inhibitors: design, synthesis and structure-activity relationships of alkylene linked bis￾galanthamine and galanthamine-galanthaminium salts. Bioorg. Med. Chem. Lett. 2000, 10, 637–639. (11) Carlier, P. R.; Du, D. M.; Han, Y. F.; Liu, J.; Perola, E.; Williams, I. D.; Pang, Y. P. Dimerization of an inactive fragment of huperzine A produce a drug with twice the potency of the natural product. Angew. Chem., Int. Ed. 2000, 39, 1775–1777. (12) Feng, S.; Wang, Z.; He, X.; Zheng, S.; Xia, Y.; Jiang, H.; Tang, X.; Bai, D. Bis-huperzine B: highly potent and selective acetylcholinest￾erase inhibitors. J. Med. Chem. 2005, 48, 655–657. (13) Munoz-Torrero, D.; Camps, P. Dimeric and hybrid anti-Alzheimer drug candidates. Curr. Med. Chem. 2006, 13, 399–422. (14) Harel, M.; Schalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, P. H.; Silman, I.; Sussman, J. L. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9031–9035. (15) Li, W.; Hao, J.; Tang, Y.; Chen, Y.; Qiu, Z. Comparative studies of X-ray determined meptazinol enantiomers with analgesic pharma￾cophore. Acta. Pharmacol. Sin. 2005, 26, 334–338. (16) Ennis, C.; Haroun, F.; and Lattimer, N. Can the effects of meptazinol on the guinea-pig isolated ileum be explained by inhibition of acetylcholinesterase? J. Pharm. Pharmacol. 1986, 38, 24–27. (17) Chen, Y. Studies on the Synthesis, Resolution and Optical Isomers of Meptazinol. Ph.D. Dissertation, Fudan University, Shanghai, P. R. China, 2004. (18) Xie, Q.; Tang, Yun.; Li, W.; Wang, X.; Qiu, Z. Investigation of the binding mode of (-)-meptazinol and bis-meptazinol derivatives on acetylcholinesterase using a molecular docking method. J. Mol. Model. 2006, 12, 390–397. (19) Savini, L.; Gaeta, A.; Fattorusso, C.; Catalanotti, B.; Campiani, G.; Chiasserini, L.; Pellerano, C.; Novellino, E.; McKissic, D.; Saxena, A. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors. J. Med. Chem. 2003, 46, 1–4. (20) Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V.
-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol. 2003, 65, 407–416. (21) Smissman, E. E.; Makriyannis, A. Azodicarboxylic acid esters as dealkylating agents. J. Org. Chem. 1973, 18, 1652–1657. (22) Pecherer, B.; Stumpf, J.; Brossi, A. Synthesis and characteristics of various 3-benzazocines, a class of potential analgesics. HelV. Chim. Acta 1970, 53, 763–770. (German). (23) Hobson, J. D.; McCluskey, J. G. Cleavage of tertiary bases with phenyl chloroformate: the reconversion of 21-deoxyajmaline into ajmaline. J. Chem. Soc. C 1967, 2015–2017. (24) Abdel-Monem, M. M.; Porgoghese, P. S. N-Demethylation of morphine and structurally related compounds with chloroformate esters. J. Med. Chem. 1972, 15, 208–210. (25) Lu, M. Design and Synthesis of Meptazinol Prodrug and Bivalent Ligands as Analgesics. Ph.D. Dissertation, Fudan University, Shanghai, P. R. China, 2005. (26) Li, W.; Wang, X.; Lau, C.; Tang, Y.; Xie, Q.; Qiu, Z. Conformational re-analysis of (+)-meptazinol: an opioid with mixed analgesic phar￾macophores. Acta. Pharmacol. Sin. 2006, 27, 1247–1252. (27) Decker, M.; Krauth, F.; Lehmann, J. Novel tricyclic quinazolinimines and related tetracyclic nitrogen bridgehead compounds as cholinest￾erase inhibitors with selectivity towards butyrylcholinesterase. Bioorg. Med. Chem. 2006, 14, 1966–1977. (28) Nicolet, Y.; Lockridge, O.; Masson, P.; Fontecilla-Camps, J. C.; Nachon, F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem. 2003, 278, 41141–41147. (29) Harel, M.; Sussman, J. L.; Krejci, E.; Bon, S.; Chanal, P.; Massoulio, J.; Silman, I. Conversion of acetylcholinesterase to butyrylcholinest￾erase: modeling and mutagenesis. Biochem. 1992, 89, 10827–10831. (30) Greig, N. H.; Lahiri, D. K.; Sambamurti, K. Butyrylcholinesterase: an important new target in Alzheimer’s disease therapy. Int. Psycho￾geriatr. 2002, 14 (Suppl. 1), 77–91. (31) Birks, J.; Grimley Evans, J.; Iakovidou, V.; Tsolaki, M. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst. ReV. 2000, 4, CD001191. (32) Bourne, Y.; Radic, Z.; Sulzenbacher, G.; Kim, E.; Taylor, P.; Marchot, P. Substrate and product trafficking through the active center gorge of acetylcholinesterase analyzed by crystallography and equilibrium binding. J. Biol. Chem. 2006, 281, 29256–29267. (33) Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727–748. (34) Li, J.; Huang, H.; Miezan Ezoulin, J. M.; Gao, X. L.; Massicot, F.; Dong, C. Z.; Heymans, F.; Chen, H. Z. Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity. Int. J. Neuropsychopharmacol. 2007, 10, 21–29. Bis-(-)-nor-meptazinols as Inhibitors Journal of Medicinal Chemistry, 2008, Vol. 51, No. 7 2035

2036 Journal of Medicinal Chemistry, 2008, VoL. 51, No. 7 Xie et al (35)Gasteiger, J; Rudolph, C: Sadowski, J. Automatic generation of 3D- (39)Wang, R; Lai, L idation of organic molecules. Tetrahedron empirical scoring functions for structure-based binding affinity predic tion. J Comput -Aided Mol. Des. 2002. 16, 11-26. (6)Gasteiger, J. Marsili, M. Iterative partial equalization of orbit ectronegativity-a rapid access to atomic charges. Tetrahedron 1980. (40)Wang, R; Lu, Y; Wang, S. Comparative evaluation of 11 scorin 36,3219-3228 functions for molecular docking. J Med. Chem. 2003. 46. 2287-2303. (7)Purcell, W. P: Singer, J. A Brief review and table of semiempirical (41) e. A. C: Laskowski. R. A. Thornton. J. M. LIGPLOT: a e ameters used in the Huckel molecular orbital method. J. Chem ta1967 to generate schematic diagrams of protein-ligand interactions. Eng.1995,8,127-134 (38)Clark. R. D. Strizhev, A: Leonard, J M.: Blake, J F: Matthew, J B Consensus scoring for ligand/protein interactions. J. Mol Graphics Modell2002,20,281-295 JM070154Q

(35) Gasteiger, J.; Rudolph, C.; Sadowski, J. Automatic generation of 3D￾atomic coordinates for organic molecules. Tetrahedron Comput. Methodol. 1990, 3, 537–547. (36) Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativitysa rapid access to atomic charges. Tetrahedron 1980, 36, 3219–3228. (37) Purcell, W. P.; Singer, J. A. Brief review and table of semiempirical parameters used in the Hückel molecular orbital method. J. Chem. Eng. Data 1967, 12, 235–246. (38) Clark, R. D.; Strizhev, A.; Leonard, J. M.; Blake, J. F.; Matthew, J. B. Consensus scoring for ligand/protein interactions. J. Mol. Graphics Modell. 2002, 20, 281–295. (39) Wang, R.; Lai, L.; Wang, S. Further development and validation of empirical scoring functions for structure-based binding affinity predic￾tion. J. Comput.-Aided Mol. Des. 2002, 16, 11–26. (40) Wang, R.; Lu, Y.; Wang, S. Comparative evaluation of 11 scoring functions for molecular docking. J. Med. Chem. 2003, 46, 2287–2303. (41) Wallace, A. C.; Laskowski, R. A.; Thornton, J. M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8, 127–134. JM070154Q 2036 Journal of Medicinal Chemistry, 2008, Vol. 51, No. 7 Xie et al